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Summary
The purpose of the work presented here was to investigate: i) in the rat isolated 
common carotid artery the population of postjunctional a-adrenoceptors, subtypes 
of a  j-adrenoceptors and their interaction with nitric oxide, ii) in the rabbit 
isolated saphenous vein the subtypes of a  j-adrenoceptors, iii) in the rabbit 
coronary ligation model of heart failure endothelium-dependent and -independent 
relaxations, contraction to NA and effect of cocaine treatment on large blood 
vessels. The major findings are briefly summarised below:
Rat carotid artery
1 The dominance of a  i-adrenoceptors is shown by the high sensitivity of 
NA or PE to prazosin and the ineffectiveness of rauwolscine except in 
non-selective concentrations. UK-14304 produced contraction and it is 
theoretically possible that UK-14304 exerts its actions through combined ocj and 
0C2 activation, but the effectiveness of prazosin and the ineffectiveness of 
rauwolscine except in non-selective concentrations, shows that even this effect is 
mediated through a  1-adrenoceptors. Thus we suggest that the population of 
postjunctional a-adrenoceptors mediating contraction of smooth muscle in the rat 
carotid artery is predominantly cl\.
2 Rat carotid artery showed moderate sensitivity to aj^-selective 
antagonists and low sensitivity to CEC. The pA2 values correlated best with the 
published affinities of these compounds for the expressed a^-adrenoceptor clone 
and poorly with those at either the expressed a ^ -  or a i a-adrenoceptor clones. 
This suggests negative evidence that contractions of the rat common carotid artery 
are mediated by n o n - a ^  non-a 13-adrenoceptors. The data is consistent with a 
functional a i D-adrenoceptor such as was reported in rat aorta.
3 In the rat isolated carotid artery, UK-14304 induced relaxation of 
NA-induced tone (but not thromboxane-induced tone) which was independent of 
ot2-adrenoceptors, functional endothelium, production of NO and cyclo-oxygenase 
products. There was no specific evidence from our study that 002-adrenoceptors 
can mediate the release of EDRF in rat carotid artery. We suggest that UK-14304 
acted as a partial agonist at a  j-adrenoceptors in this artery.
4 Inhibition of NO synthesis by L-NAME results in significant 
vasoconstriction. Also, L-NAME prevented the relaxation of rat carotid artery by 
acetylcholine. Thus we suggest that both basal and stimulated release of nitric 
oxide can regulate vascular tone in this artery.
5 Mechanical disruption of the vascular endothelium (to an extent which 
prevented vasodilation by acetylcholine) reduced, but did not abolish the ability of 
L-NAME to produce contraction. This suggests an extra-endothelial site for nitric 
oxide synthesis in rat common carotid artery.
6 The effect of UK-143 04 was significantly enhanced in the presence of 
L-NAME. Inhibition of nitric oxide synthase with L-NAME potentiates responses 
to PE and UK-14304 but not to NA. Mechanical disruption of the vascular 
endothelium mimicked the effect of L-NAME on contractile responses to 
UK-14304 and PE consistent with L-NAME inhibiting endothelium-derived nitric 
oxide synthase. There was one unexplained difference between L-NAME and 
denuding endothelium. Although L-NAME did not increase sensitivity to NA, 
mechanical disruption increases potency of NA. Overall the results suggest that 
constitutive NO activity has substantial inhibitory influence on vasoconstrictor 
responses to PE and UK-14304 but not to NA.
7 Since L-NAME greatly potentiates responses to UK-14304, a series of 
experiments were conducted to see whether other stimuli that produces 
submaximal contraction would have a similar synergistic effect. Submaximal
contraction with KC1 increased responses significantly, but inducing tone with 
PE, U-46619 and 5HT had no effect on responses to UK-14304. The presence of 
All increased responses though less than KC1. Overall the greatest influence 
found was blockade of nitric oxide synthase.
Rabbit saphenous vein
8 We investigated the a  j-adrenoceptor subtypes of rabbit saphenous vein 
which has a mixed functional population of and oc2-adrenoceptors. The 
strategy was based on using the a\-adrenoceptor "selective" agonist, PE. 
Prazosin competitively inhibited contractile responses to phenylephrine with pA2 
value of 8 , WB-4101 had a pA2 of 8 .6  but a low Schild plot slope, while low 
potency was found with 5MU (pA2 7.2) and HV-723 (pA2 7.97). This data is not 
consistent with a definitive for or a  in  and taken alone the evidence from 
prazosin is in favour of ocil as defined by Muramatsu et al., (1990). However the 
"selective" a 2-adrenoceptor antagonist delequamine inhibited phenylephrine- 
induced contractions. Overall the data is consistent with phenylephrine-induced 
contractions being mediated by a p  and ot2-adrenoceptors. The best estimate of 
subtype of a  j-adrenoceptor mediating contraction is a 1L due to the relatively low 
absolute pA2 values for prazosin.
"Heart failure1* model
9 We investigated endothelium-dependent or -independent relaxations and 
sensitivity and neuronal uptake of NA at the level of larger vessels (thoracic aorta 
and vena cava; left renal artery and left renal vein; lateral saphenous artery and 
lateral saphenous vein and finally central ear artery and marginal ear vein) in a 
model devised to mimic heart failure. The model presented here is the rabbit
coronary ligation model in which myocardial infarction was produced in male 
New Zealand white rabbits (2.6kg-3.0kg) by ligation of the marginal branch of the 
left descending coronary artery. It was prepared by Royal Infirmary, Glasgow. 
The development of chronic heart failure was allowed to proceed over either eight 
or sixteen weeks. The results of the haemodynamic measurements suggest that 
short-term (8  week) and long-term (16 week) coronary ligation in the rabbits each 
corresponds to a model of experimental asymptomatic left ventricular dysfunction 
or minimally symptomatic LVD rather than of clinical heart failure. LVD was 
confirmed by echocardiographic measurement of ejection fraction.
10 Acetylcholine was chosen as endothelium-dependent vasodilator and 
sodium nitroprusside as an endothelium-independent vasodilator. ATP and 
adenosine were also chosen as vasodilators to study the function of endothelium 
in addition to acetylcholine. We used cocaine (lfJ.M) to inhibit neuronal reuptake 
of noradrenaline. The properties of vessels from ligated rabbits were compared 
with sham operated controls. The investigation was blind with respect to sham or 
ligated.
11 The results led to 3 major conclusions with respect to the model. First, the 
relaxation responses to acetylcholine, sodium nitroprusside, ATP and adenosine 
were not impaired. Second, vasoconstrictions to noradrenaline were unaltered. 
Third, contractions to KC1 (125mM) were preserved in large vessels (arteries and 
veins) in coronary ligated rabbits after 8 or 16 weeks compared with a normal 
control population.
12 The results of our experiments in this model of heart failure suggest that 
vasoconstriction to noradrenaline and normal stimulation of endothelial NO are 
preserved in larger peripheral conduit vessels. The changes demonstrated here 
provide a useful model for studying the progression of Left ventricular dysfunction 
to heart failure.
ix
13 In relaxation responses to acetylcholine ear vein, saphenous vein and aorta 
were most sensitive in terms of threshold and concentration producing 50% 
maximum relaxation of tone. Saphenous vein and aorta produced the greatest 
maximum relaxations (78-90%). Saphenous artery and ear artery had the poorest 
responses to acetylcholine.
14 In contraction responses to NA aorta, ear artery and ear vein were the most 
sensitive preparations (pD2 values: 9.96, 7.04 and 7.8 respectively). Renal artery 
and aorta had relatively very large maximum responses to NA among the arteries 
(6.7 and 4.3g respectively) and saphenous vein had greatest maximum response 
among the veins (2.9g).
15 In effect of cocaine (lp,M) only in ear artery and saphenous artery or vein 
were the 3rd CRC to NA i.e. in the presence of cocaine, shifted to the left indicating 
increased sensitivity to NA. These results suggest that among arteries and veins that 
were studied, ear artery and saphenous artery or vein have innervation which can 
influence sensitivity to NA. Also we investigated the network of sympathetic 
nerves stained by glyoxylic acid. In agreement with the functional results, it was 
shown that ear artery and saphenous artery or vein have dense innervation but in 
other preparations sparse innervation or in vena cava no nerves were observed.
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CHAPTER 1 
General Introduction
1.1 Historical perspective
Oliver & Schafer demonstrated in (1895) that injection of extracts of adrenal 
gland caused a rise in arterial pressure in vivo. The initial view about 
adrenoceptors held by Elliot (1905) was that adrenaline was the most likely 
mediator of sympathetic neurotransmission. He suggested that adrenaline is 
liberated from sympathetic nerve ending and acts on the effector cells. Dale 
(1906) provided some of the earliest experimental evidence that adrenoceptors 
could be differentiated into two classes. He observed that excitatory responses of 
various organs to adrenaline and nerve stimulation were paralysed by the ergot 
alkaloids, whereas inhibitory responses were not. Barger and Dale (1910) 
demonstrated that noradrenaline mimicked the effects of sympathetic nerve 
stimulation more closely than adrenaline.
Cannon and Rosenblueth (1933) explained the fact that adrenaline could excite 
some smooth muscles but inhibit others by calling sympathetic transmitter 
sympathin, to emphasise that its actions were not identical to adrenaline. To 
explain why released sympathin or exogenous adrenaline could excite some 
smooth muscles but inhibit others they postulated that it combined with one of 
two hypothetical substances. These substances made the sympathin excitatory or 
inhibitory so that two sympathins could be produced: sympathin E (excitatory) or 
sympathin I (inhibitory).
In (1948) Alquist noted the effects of five catecholamines on eight different 
physiological functions and clearly showed that the order of potency of the 
catecholamines for five of the physiological functions was markedly different 
from the order of the potency for the other three functions. He concluded that the 
differences in potency orders could only be explained by assuming differences in 
the receptors. Therefore he classified adrenoceptors initially into a  and P 
subtypes. Effector cells with a-adrenoceptors had a high sensitivity to adrenaline
1
and noradrenaline but were practically insensitive to isoprenaline. Those tissues 
with p-adrenoceptors were sensitive to isoprenaline but less sensitive to 
adrenaline or noradrenaline.
1.2 a-adrenoceptors
The a-adrenoceptors are intrinsic membrane glycoproteins that mediate a variety 
of important sympathetic nervous system responses. They mediate a variety of 
functions and have been of major interest for many years as targets for drug 
action, and implicated in many human diseases.
The original proposal for the subclassification of a-adrenoceptors was based on 
pharmacological differences observed using a-adrenoceptor blocking agents on 
peripheral presynaptic and postsynaptic a-adrenoceptors in the perfused cat 
spleen (Cubeddu et al., 1974). The discovery of presynaptic a-adrenoceptors and 
their role in the modulation of noradrenergic neurotransmission provided the 
stimulus for the subclassification of a-adrenoceptors. This subclassification 
developed as a result of the pharmacological differences between presynaptic 
a 2-adrenoceptors that mediate inhibition of the release of noradrenaline from 
sympathetic nerve terminal and postsynaptic a  j-adrenoceptors. It was suggested 
that the postsynaptic receptor should be referred to as cl\ while the presynaptic 
receptor should be called a 2 (Langer, 1974). Therefore a-adrenoceptors were 
divided into two subtypes, termed a j  and a 2 dependent on anatomical location 
and function.
Differences in relative potencies of agonists which stimulate and antagonists 
which block these receptors have led to the conclusion that postsynaptic receptors 
are qualitatively different from presynaptic receptors. Classically, identification 
of a-adrenoreceptors should be based on the relative affinity and potency of
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different agonists and antagonists in effector tissues, and this was shown to be the 
case with these cci -and o^-adrenoceptors which were originally found to be 
postsynaptically and presynaptically located respectively (Langer, 1974; Starke et 
al, 1974).
1.3 Evidence for the existence of postsynaptic aj - and a 2 -adrenoceptors 
on vascular smooth cells
Subsequent work in this field, using a number of selective agonist and antagonist 
drugs, has confirmed the existence of otp and ct2-adrenoceptors postsynaptically 
and allowed characterisation of their location and function (Docherty & McGrath, 
1980).
Although the demonstration of postjunctional a 2-adrenoceptor in isolated vascular 
smooth muscle preparations is difficult, particularly in arteries, there is clear 
evidence for the presence of postjunctional a  2 -adrenoceptors as well as 
oci -adrenoceptors on the smooth muscle of many vascular preparations 
(M cGrath, 1982). Although the a\-adrenoceptor subtype linked to 
vasoconstriction is the predominant postsynaptic receptor in vascular smooth 
muscle, the postsynaptic ot2-adrenoceptor subtype also mediates constriction of 
vascular smooth muscle (McGrath et al, 1989).
1.4 ct2 -adrenoceptors on vascular smooth muscle cells
The presence of postsynaptic a 2-adrenoceptors has been demonstrated in many 
studies in vivo, but only a limited number of isolated vascular tissues are known to 
exhibit a typical postsynaptic o^-adrenoceptor-mediated response. The presence 
of postjunctional a 2-adrenoceptors on the smooth muscle of the rat tail artery has
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been demonstrated in binding studies with selective radioligands (Weiss et a l, 
1983) and activation of these ot2-adrenoceptors produces contractile responses 
(Rajanayagam & Medgett, 1987). Postsynaptic a-adrenoceptors possess the 
ot2-subtype in the rat isolated saphenous vein (Cheung, 1985), the rat isolated 
femoral vein (Downing et al., 1986), the rabbit isolated saphenous vein 
(Schumann & Lues, 1983) and the rabbit isolated ear vein (Daly et al., 1988), as 
defined by responsiveness to selective agonists and the competitive inhibition by 
selective antagonists with a high specificity. The existence of 
a 2-adrenoceptor-mediated vasoconstriction was also documented in peripheral 
human vessels (Taddei et al., 1988).
1.5 a 2 -adrenoceptors: in vivo and in vitro
Many haemodynamic studies of whole organ preparations have documented 
vasoconstriction to both a j -  or a  2-adrenoceptor agonists, which indicated the 
postsynaptic location of both receptor subtypes on vascular smooth muscle 
(Docherty & McGrath, 1980; O'Brien et al, 1985). In spite of the availability of 
a-adrenoceptors agonists with proven selectivity for either subtype in vivo, there 
are few examples in vitro of blood vessels that possess a functional population of 
postjunctional a 2-adrenoceptors. Several explanations have been put forward to 
explain the elusive nature of this subtype in vitro. It has been suggested that 
postjunctional a 2~adrenoceptors are located on small arterioles which, because of 
their size, are not normally accessible for examination in vitro (McGrath, 1982). 
An additional explanation for the difficulty in demonstrating postjunctional 
a 2-adrenoceptors in vitro may be the lack of humoral agents normally present in 
the whole animal (Schumann & Lues, 1983).
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1.6 Selectivity of some agonists and antagonists
In general, a-adrenoceptors of the type are most effectively activated by 
phenylephrine and antagonised by prazosin, selective for the a  \-adrenoceptors 
(Cambridge et al., 1977). Responses to a-adrenoceptor agonists in the vast 
majority of isolated vascular preparations, particularly arterial vessels, have been 
shown to be sensitive to prazosin (McGrath, 1982). YM-12617 is a potent and 
highly selective a  \-adrenoceptor antagonist. The a  \-adrenoceptor antagonist 
activity of YM-12617 was found to be more potent than that of prazosin in 
isolated rabbit aorta, urinary bladder base, urethra and prostate (Honda et al., 
1985). In the isolated rabbit aorta, YM-12617 competitively antagonised 
noradrenaline- and phenylephrine-induced contraction with pA2 values of 10 .2  
and 9.95, respectively. Based on the pA2 and pKj values of in vitro assay, 
YM-12617 has a greater than 5000 times higher affinity for a p  than for 
a 2 -adrenoceptors. This inhibitory action of YM-12617 against the 
a  i-adrenoceptor-mediated pressor response was over 2 0 0 0  times greater than that 
against the a 2-adrenoceptor-mediated pressor effect of UK-14304 in pithed rats 
(Honda et al., 1987). The rauwolfia alkaloids, rauwolscine and yohimbine were 
originally shown to be highly selective a 2-antagonists (Weitzell et al., 1979).
The a-adrenoceptors classified as a 2 are preferentially stimulated by clonidine 
and inhibited by rauwolscine. Radioligand-binding studies have led to a 
comparable subclassification (Wood et al., 1979). Although clonidine has some 
degree of selectivity for a 2-adrenoceptors (Starke et al., 1974), it is not a full 
agonist and has partial agonist effects on a  \-adrenoceptor subtype (Grant & 
Scrutton, 1980). UK-143 04 is a full agonist at a 2-adrenoceptors in various 
pharmacological preparations (Grant & Scrutton, 1980; Cambridge, 1981). Also 
BHT-920 has been used as a selective a  2-adrenoceptor agonist (Kobinger & 
Pichler, 1983).
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Noradrenaline stimulation of both postjunctional 0 4 - and a 2-adrenoceptors can be 
demonstrated in pithed rabbits, using the sequential administration of the 
antagonists prazosin and rauwolscine, the combination of which produces a 
greater effect than either antagonist alone (McGrath et al., 1982).
1.7 Location of postsynaptic aj-adrenoceptors
The aj-selective adrenoceptor antagonist prazosin was more effective in blocking 
the responses to noradrenaline released by nerve stimulation than in antagonising 
the same end-organ responses induced by exogenous noradrenaline (Langer & 
Shepperson, 1982). Similar results were obtained with the use of other a-selective 
antagonists (Yamaguchi & Kopin, 1980).
The fact that a  \ -adrenoceptor antagonists were found to be more effective at 
blocking responses to sympathetic nerve stimulation than they were at blocking 
equivalent sized responses to exogenous noradrenaline, led to the suggestion that 
postjunctional a  \-adrenoceptors were neurogenic receptors, while 
a,2 -adrenoceptors were located extrajunctionally, responding to circulating 
catecholamines (McGrath, 1982).
Exogenous noradrenaline can activate both a j -  and (X2-adrenoceptors mediating 
vasoconstriction, whereas the transmitter released by nerve stimulation elicits 
vasoconstriction through the activation of a  j-adrenoceptors (Langer & 
Shepperson, 1982). It is therefore possible that the oti-adrenoceptor predominates 
in the adventitial-medial border, where most of the noradrenergic nerve terminals 
are present, whereas the postsynaptic oc2-adrenoceptors are located mainly near 
the intima and therefore may be the target of circulating catecholamines. The 
postsynaptic ct2 -adrenoceptor subtypes also mediates contraction of vascular 
smooth muscle and appears to be located close to the intima of blood vessels,
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where they may be the target of circulating catecholamines rather than neuronally 
released noradrenaline (Langer & Hicks, 1984).
1.8 Role of calcium in responses via a-adrenoceptors
Pressor responses to a 2-adrenoceptor agonist in vivo can be blocked by calcium 
channel blocking drugs such as verapamil, nifedipine and diltiazem (Cavero et al., 
1983; Dunn et al, 1991b). Furthermore, contractions of isolated vascular smooth 
muscle elicited by a  2-adrenoceptor activation are reduced by lowering the 
calcium concentration and by calcium channel blocking drugs in the rat tail artery 
(Su, et al., 1986). The enhancing effect of a 2-adrenoceptor agonists on responses 
of the rat tail artery to a  2 -adrenoceptor agonists involves an increase in 
Ca2+-influx into smooth muscle cells through Ca2+ channels that are opened 
when a 2-adrenoceptors are activated (Xiao & Rand, 1989).
In most instances, stimulation of postjunctional a  i-adrenoceptors elevates [Ca2+]j 
by entry of extracellular Ca2+ into the cell and also the release of Ca2+ from 
intracellular stores. Contractions evoked by a 2-adrenoceptor stimulation are 
known to rely more heavily on the influx of extracellular calcium than those 
caused by aj-adrenoceptors (Reid & McGrath, 1985).
1.9 Effect of different physiological factors
The presence of Bay K-8644 or inducing tone with prostaglandin F2ot, enhanced 
responses to the selective a 2-adrenocetor agonist BHT-920 which were 
prazosin-resistant and rauwolscine-sensitive, in canine isolated saphenous artery 
and portal vein respectively (Sulpizio & Hieble, 1987). Furthermore, the 
physiological stimulant angiotensin II (All), enhances postjunctional
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a 2-adrenoceptor function in some venous preparation (Schumann & Lues, 1983; 
Daly etal., 1988b).
In the pithed rat, the responses to the a-adrenoceptor agonists were differentially 
affected by respiratory alkalosis and acidosis. Responses to ai-adrenoceptor 
agonist were greater in alkalosis; those to ot2-adrenoceptor agonist were better in 
acidosis (O'Brien et al, 1985).
Significant potentiation of noradrenaline-induced contraction was observed in 
canine internal carotid arteries treated with prazosin (lOnM), whereas yohimbine 
(lOnM) attenuated the time-dependent potentiation. The contractile responses of 
isolated canine basilar and internal carotid arteries to noradrenaline are potentiated 
during the course of the experiment, which is iikely to be related, in part, to an 
enhancement in ct2-adrenoceptor mediated contraction (Kawai et al., 1991).
There is much evidence, especially from studies in pithed rats, that 
a 2-adrenoceptor-mediated responses are dependent on the physical environment. 
It has been suggested that the ct2-adrenoceptor exists in different conformational 
states depending on tissue or species, according to the presence of co-factors in 
the immediate vicinity of the receptor (Alabaster et al., 1986). The possibility 
existed therefore that a 2-adrenoceptors could differ sufficiently to allow the 
identification of antagonists which could be targeted to different tissues or 
different ct2-sites. On balance the data are compatible with the view that 
a 2 -adrenoceptor-mediated responses in vascular smooth muscle are more 
dependent on the physiological environment than are responses mediated by 
ai-adrenoceptors (Alabaster & Davey, 1984).
1.10 Functional subclassification of vascular -adrenoceptors
Since the establishment of two general subtypes of a-adrenoceptors (a j and a 2), a 
further subclassification for a  \-adrenoceptors has been suggested (McGrath, 
1982). McGrath provided evidence that a\-adrenoceptors are a heterogeneous 
group of receptors, and that postjunctional responses mediated by 
a  i-adrenoceptors, could not be explained adequately on the basis of a single 
receptor subtype. He proposed a subdivision of a\-adrenoceptors into a j ^  and 
a  I B .  It was suggested that both phenethylamines and non-phenethylamines were 
efficacious agonists at the subtype but a^-adrenoceptors were activated only 
by phenethylamines. In 1985, Drew first suggested that the variety of pA2 values 
for prazosin and yohimbine in many tissues may reflect a possible heterogeneity 
of a  i-adrenoceptors. Flavahan & Vanhoutte (1986) suggested that there were two 
distinct subtypes of a  \ -adrenoceptors which could be distinguished by their 
affinities for both prazosin and yohimbine in the blood vessels ( a m  and <Xil 
according to their High or Low affinity for prazosin), a m  has a high affinity for 
both drugs (pA2 values greater than 9 for prazosin and greater than 6.4 for 
yohimbine), and the other (am ) has a low affinity for drugs (pA2 values less than 
9 and 6.2 respectively). Muramatsu and co-workers (1990) extended this 
functional subclassification of a  \ -adrenoceptors of various vascular smooth 
muscle preparations with the use of five a-adrenoceptor competitive antagonists 
(phentolamine, yohimbine, WB-4101, prazosin and HV-723) and irreversible 
antagonist, chloroethylclonidine as show in the table. Their classification scheme 
for a  i-adrenoceptor subtypes is based primarily on differential affinities for 
prazosin.
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Table 1.1
Characteristics of a^-adrenoceptor subtypes in blood vessels proposed by 
Muramatsu et al, (1990)
subtype antagonist potency (pA2 value)
a lH prazosin > HV-723,WB-4101>yohimbine
(>9.5) (8.0-9.3) (>6.5)
a  1L prazosin , HV-723, WB-4101 >yohimbine
(8 .0-9.0) (6.4>)
HV-723>WB-4101>prazosin >yohimbine
(>9.0) (>8.4) (8.3>) (>6.5)
In some tissues such as rabbit thoracic aorta, both affinities for prazosin are 
detected, suggesting the existence of prazosin-high ( a m )  and -low 
( a 1L)-adrenoceptors. In such cases, the slope of Schild plot for prazosin 
significantly deviates from unity (Oshita et al., 1993).
In tissues with low affinity for prazosin, the pKg values for prazosin are 
approximately 8.5, which is 10 times less in affinity than for a  ^ -adrenoceptors. 
HV-723 (Kohno et al., 1994) can subdivide the a iL _adrenoceptor into two 
subtypes: cl\l (HV723-1ow, <lnM) and (neither a j H or a ^ )  (HV723-high). 
It is a useful antagonist for the subclassification of the prazosin-low affinity sites 
(Muramatsu et al., 1995).
From the relative potencies of the a-antagonists, the subtype is the most 
sensitive to prazosin and the a  in  subtype is more sensitive to HV-723 and
suscep tib ility  to 
chloroethylclonidine
sensitive (a^B)
insensitive
insensitive
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WB-4101 than prazosin. The a j L subtype shows equal affinity for prazosin, 
HV-723 and WB-4101. From the absolute pA2 values for the a-antagonists, 
prazosin discriminates a 1H and a 1L, and HV-723 further distinguish between a 1L 
and a 1N. WB-4101 and 5-methylurapidil are selective for a^-adrenoceptor 
subtypes and spiperone has been reported to have a 10 -fold higher affinity for 
a j B- than for a  ^ -adrenoceptors (Michel et al, 1989).
a 1H-adrenoceptors were, at one point in time, subdivided into four subtypes: a ^ ,  
a l B,  a ic  anc* a l D.  Since then the cloned a ^ h a s  been renamed a j a and it is 
believed to be equivalent of the pharmacologically defined, tissue type 
(Bylund et ah, 1994). The cloned, formerly named expand (a ia/d) are n o w  
considered equivalent, called a lcj and considered the counterparts of the 
functionally defined a m . Thus, the new nomenclature of a  j-adrenoceptors with 
high affinity for prazosin recently acknowledged that the cloned a j c-adrenoceptor 
corresponds to the classical a 1A-adrenoceptor, the cloned a  ^ -adrenoceptor 
equivalent of a  13-adrenoceptor and the cloned ai^-adrenoceptor corresponds to 
the classical aip-adrenoceptor (Hieble et al., 1995). Therefore in the new 
nomenclature a  1 3 -adrenoceptor can be subdivided into three subtypes: a ^ ,  o^ib, 
and a  id.
In the dog carotid artery a high pKB value (9.7) for prazosin was estimated. 
However, the pKB values for WB-4101 and 5-methylurapidil were relatively low 
(8.2 and 7.2, respectively). Pretreatment with CEC, which produces relatively 
selective inactivation of the cloned a i B and a i c  subtypes, remarkably attenuated 
the contractile response to noradrenaline. These results suggest that the 
a  1-adrenoceptor of dog carotid artery belongs in the a m  group of the functional 
subclassification and further corresponds to the cloned a i B subtype. The 
a  1-adrenoceptor with prazosin-high affinity (am ) of rabbit thoracic aorta (am ) is 
a similar subtype to that of dog carotid artery (Oshita et al., 1993).
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1.11 Subtypes of a 2 -adrenoceptors
a 2-Adrenoceptor is defined as one that is sensitive to both the physiological 
catecholamine agonists, noradrenaline and adrenaline, as well as selective 
agonists, such as BHT-920 and UK-14304, and is antagonised by agents such as 
rauwolscine and yohimbine. a 2-Adrenoceptor subtypes can be divided into at 
least four subtypes: o t 2 A » a 2 B ,  a 2 C  anc* <*2D based on ligand binding and 
molecular cloning studies. All known o^-adrenoceptor can be activated by 
noradrenaline and adrenaline, and there is no evidence that these physiological 
catecholamines show significant selectivity between any of the known 
a 2-adrenoceptor subtypes. All subtypes can be blocked by yohimbine and 
rauwolscine, although the affinity can vary substantially between subtypes. 
Some a 2-adrenooceptor subtypes have a high affinity for prazosin, previously 
thought to interact only with a  i-adrenoceptors, and others have a relatively low 
affinity for rauwolscine, compared to other a 2-adrenoceptor antagonists. All 
a 2-adrenoceptors appear to be linked to inhibition of adenylate cyclase as one, 
but not only, mechanism of signal transduction. Prazosin and another 
ai-adrenoceptor antagonist, ARC-239, have high affinity for a 2B-adrenoceptor, 
and low affinity for a 2A"acirenoceptor. The partial a-adrenoceptor agonist, 
oxymetazoline, is more selective to the a 2A-adrenoceptor than other subtypes. 
The a 2c_adrenoceptor is similar to the a 2B-adrenoceptor with respect to a 
relatively high affinity for prazosin, ARC-239, and spiroxatrine, but it has a 
higher affinity for rauwolscine. WB-4101 is more selective for a 2c- versus 
a 2Badrenoceptors. a 2o-Adrenoceptor has a lower affinity for rauwolscine than 
the other subtypes and , like the a  2 A_adreno cep tor, a low affinity for prazosin, 
spiroxatrine and ARC-239 (Ruffolo, et al, 1993; Bylund et al, 1994).
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1.12 Signal transduction mechanisms
a  i-Adrenoceptors belong to that family of receptors which initiate their signals in 
target cells by increasing free cytosolic Ca2+ levels. Han and colleagues (1987b) 
proposed that a ^ -  and o^g adrenoceptors activated distinct signal transduction 
mechanisms to increase cytosolic Ca2+ level. They suggested that the 
cqg-subtype activated formation of inositol (1,4,5) triphosphate and released 
stored intracellular Ca2+, whereas the a ^ -su b ty p e  increased influx of 
extracellular Ca2+ through an inositol phosphate-independent mechanism.
Experiments with exogenous noradrenaline in rat vas deferens led to the view that 
the a iA  subtype activates calcium influx through dihydropyridine sensitive 
channels whereas the a ig  subtype activates phosphatidylinositol breakdown 
followed by calcium mobilisation from intracellular stores (Han et al., 1987b). 
These receptors activate a G protein, which in turn activates a phosphoinositide 
specific phospholipase C. This enzyme cleaves inositol (1,4,5) triphosphate from 
a membrane phospholipid, and Ins (l,4,5)p3 mobilises stored pools of 
intracellular Ca2+. Diacyl glycerol is also released from this reaction, which acts 
synergistically with Ca2+ to activate protein kinase C. However, it is known that 
a l^-adrenoceptors can also couple to InsP formation and mobilisation of 
intracellular Ca2+, while the aig-adrenoceptor can couple to voltage-gated Ca2+ 
influx (Minneman, 1988). The relative antagonist potency observed with the 
S(+)- versus R(-)- isomer of niguldipine (approximately 30 fold) is fully 
consistent with reported characteristics of a  ^ -adrenoceptors (Boer et al., 1989).
1.13 Endothelium-Derived Relaxing Factor (EDRF)
Prostacyclin (PGI2), a potent vasorelaxant, was the first endothelium-derived 
vasoactive substance discovered in the late 1970s (Moncada & Vane, 1979).
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Later it was demonstrated that the vascular relaxation induced by acetylcholine 
was dependent on the presence of the endothelium (Furchgott & Zawadzki, 1980). 
They observed that acetylcholine relaxed rings or strips of rabbit aorta in vitro, 
but only if  endothelium cells were present in the preparation. Later Furchgott 
(1983) provided evidence that this effect was mediated by a labile non prostanoid 
humoral factor, known as EDRF (endothelium-derived relaxing factor).
1.14 Agonists that stimulate production of EDRF
Endothelium-dependent relaxation occurs in response to a variety of substances 
including platelet derived products such as adenine nucleotides (ATP, ADP) 
(Furchgott & Zawadzki, 1980; De Mey & Vanhoutte, 1981). Other numerous 
compounds, such as substance P, histamine (Moncada et al., 1991) can release 
EDRF. This observation has since been confirmed and extended, and it was 
recognised that release of EDRF was responsible for the dilator response to 
acetylcholine and bradykinin in a variety of animal and human arteries and veins 
(Thom et al., 1987). Nitrovasodilators induce vascular relaxation by 
endothelium-independent mechanisms (Furchgott, 1984).
Release of EDRF was observed under basal conditions as well as after stimulation 
with acetylcholine (Martin et al., 1985). Contrary to the PGI2 synthesis, the 
production of ERDF is highly dependent on extracellular Ca2+. An elevation in 
the intracellular free Ca2+ concentration ([Ca2+)]j has been shown to be an 
absolute prerequisite for the acute increase in the synthesis of EDRF in the 
endothelial cells induced by either receptor-dependent agonists such as 
acetylcholine, ATP, and bradykinin or receptor-independent compounds such as 
calcium ionophores or thimerosal (Luckhoff et al., 1988).
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1.15 Identification of EDRF as NO
Based on the similarities in the pharmacological behaviour of EDRF and NO 
generated from acidified NO2, it was suggested in 1987 that EDRF may be NO. 
The first evidence for the formation of NO by mammalian cells came from 
experiments in which EDRF released from vascular endothelial cells was detected 
by the chemical means used to identify NO. Much evidence strongly suggested 
that EDRF is NO (Palmer et al., 1987).
The amino acid L-arginine was shown to be the precursor for the synthesis of NO 
by vascular endothelial cells. Endothelial cells, cultured in the absence of 
L-arginine for 24 hour prior to the experiments, showed a decrease in the release 
of NO induced by bradykinin and A23187 which could be restored by L-but not 
D-arginine (Palmer et al., 1988). NO is formed from L-arginine by 
NADH-dependent nitric oxide synthase, which is also a calcium-sensitive 
enzyme, and is located in the endothelial cytosol. Endogenous NO produced by 
endothelial cells diffuses passively into neighbouring vascular smooth muscle 
cells, where it binds to the heme component of guanylyl cyclase, thereby 
activating the enzyme, resulting in increased cyclic GMP production and 
relaxation by dephosphorylation of myosin light chain. Smooth muscle tone 
depends on the cytoplasmic calcium concentration and NO has been reported to 
inhibit calcium release from intracellular stores and calcium influx through 
receptor operated channels (Moncada et al., 1991).
1.16 Physiology of NO
Three isozymes of NOS (NO synthase) have been characterised and all isoforms 
of nitric oxide synthase utilise L-arginine as the substrate. Despite substantial 
homology among the gene sequences of the three isozymes, their physiologic
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actions differ markedly and the predominant isozyme in endothelial cells is a 
constitutive form. A second isozyme of NOS, which is predominantly found in 
activated macrophages, is also expressed in endothelial cells and vascular smooth 
muscle cells exposed to cytokines. This inducible form of NOS does not require 
calcium or calmodulin for its activity and, once expressed, produces NO in an 
unregulated fashion. The third isozyme of NOS is found predominantly in the 
central nervous system and has not been identified in endothelial cells (Dinerman 
et al, 1993; Anggard, 1994).
The vascular endothelial cells are the only cells to possess both the constitutive 
and inducible NO synthases. The production of NO can be stimulated by several 
agonists acting on different cell-surface receptors and using distinct intracellular 
signal transduction pathways. NO is not stored but diffuses freely from its site of 
formation whereas classical mediators are frequently stored in granules and 
released specifically. It is rapidly metabolised to nitrite and nitrate in the presence 
of oxygen with a half-life of approximately 3-5 seconds; the half-life is shortened 
by the presence of free radicals such as superoxide anion and is, thus, prolonged 
by free radical scavengers such as superoxide dismutase. It is soluble both in 
water (up to 2mmol L at 20 C and one atmosphere) and lipid (Busse et al., 1993).
1.17 Inhibition of NO
The effects of EDRF were shown to be inhibited by Hb, methylene blue, and 
other agents such as dithiothreitol and hydroquinone (Griffith et al., 1984). 
Several analogues of L-arginine are inhibitors of vascular nitric oxide (NO) 
synthase. They inhibit NO synthase in an enantiomerically specific manner and 
act as competitive inhibitors of all three isozymes of NOS and, thus, have been 
used extensively in investigations of NO metabolism. NG-monomethyl-L- 
arginine (L-NMMA), N-iminoethyl-L-omithine (L-NIO) and N0 -nitro-L-arginine
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methylester (L-NAME) are inhibitors of NO synthase in the vascular endothelium 
in vitro and in vivo. They are specific inhibitors of both the constitutive and 
inducible NO synthases (Rees et al., 1990).
1.18 Vasodilation via a 2 -adrenoceptors on endothelium
Stimulation of the release of endothelium-derived relaxing factor nitric oxide 
(EDRF), a powerful vasodilator, mediating relaxation through activation of 
soluble guanylate cyclase in neighbouring smooth muscle cells (Moncada et al., 
1991 ), has been shown to oppose the effects of a-agonists and of other 
vasoconstrictors. The receptors on the endothelium mediating the relaxation 
response to noradrenaline were tentatively classified as ot2-adrenoceptors (Cocks 
& Angus, 1983; Angus etal., 1986).
In isolated arteries and veins endothelium dependent vasodilatory responses to 
clonidine and to other ct2 -agonists can efficiently counteract their direct 
constrictor effects on vascular smooth muscle cells via this endothelial pathway. 
Removal of the endothelium in isolated arteries (Cocks & Angus, 1983; Tschudi, 
et al., 1991) or exposure to methylene blue, an inhibitor of EDRF-mediated 
activation of guanylate cyclase (Gold et al., 1990; Martin, 1985) may increase the 
vasopressor effects of clonidine by several orders of magnitude, emphasising the 
significance of ot2-mediated endothelial-dependent vasodilation in certain 
vascular beds.
It has been reported that a  2-adrenoceptor agonists produced vasodilation in 
isolated dog coronary arteries (Angus & Cocks, 1983; Angus et al., 1986 ), in dog 
femoral and pulmonary arteries and veins (Miller & Vanhoutte, 1985) and in rat 
tail arteries (Matsuda et al., 1985). It was postulated that this was due to 
activation by the agonists of receptors on the endothelium to release EDRF.
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To illustrate the a 2-adrenoceptor-mediated activity directly, it is necessary to have 
intact endothelium, and -and P-adrenoceptor antagonists present. The signal is 
quite powerful in some circumstances as it has been demonstrated that this EDRF 
release can alter the maximum response and shift the concentration response 
curves for the contractile effects of noradrenaline in dog and in pig coronary 
arteries (Cocks & Angus, 1983).
In pig the contractions via a-adrenoceptors are small, and endothelium dependent 
relaxations via a 2-adrenoceptors are large, in the coronary and carotid arteries 
which perfuse the vital organs. It is suggested that in the state of activation of the 
sympathetic nervous system, arterial tone in response to a-adrenoceptor 
stimulation may be regulated not only by a-adrenoceptors on vascular smooth 
muscle but also by those on endothelium, through release of endothelium derived 
relaxing factor (EDRF) via a 2-adrenoceptors (Ohgushi et al., 1993).
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CHAPTER 2
Investigation of ai-Adrenoceptor 
Subtypes and Effect of Nitric Oxide in 
Rat Common Carotid Artery
Section 1: Introduction
Much of the experimental work on the large arteries in rat has been concentrated 
on the aorta, which is the largest artery in the rat. However aorta contains a 
substantial component of collagen and elastin with few smooth muscle cells 
relative to its size. We wished to characterise a large artery which might contain 
relatively more smooth muscle cells and less connective tissue and therefore be 
more suitable for physiological analysis. We anticipated similar properties to the 
aorta for which there is more background information. Although some previous 
studies of the rat carotid artery made with perfusion-system, in which a carotid 
artery was perfused (Patemo et al, 1994), there are other studies in rat carotid 
artery using ring preparations. Hongo and colleagues (1988) used rat carotid 
artery as a ring to investigate effects of aging and hypertension on 
endothelium-dependent vascu lar relaxation . They found that 
endothelium-dependent relaxation of the carotid artery is impaired in old rats and 
in hypertension.
Previous studies in rat carotid arteries concentrate more on effects of different 
disorders. Since sympathetic stimulation and production of nitric oxide have 
great influence on the cerebral circulation, our experiments were designed to 
demonstrate the population and subtypes of a-adrenoceptors and effects of nitric 
oxide in this artery.
There are many reports showing that contractions of vascular smooth muscle cells 
by a-adrenoceptor agonists are depressed in the presence of endothelium or basal 
release of NO (Carrier & White, 1985; Young & Vatner, 1986; Kaneko & 
Sunano, 1993; Maclean et al., 1993). We investigated effects of removal of the 
endothelium and inhibition of basal nitric oxide on a-adrenoceptor agonists in this 
artery.
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Considerable quantitative variation between different laboratories exists with 
regard to the demonstration of the vasoinhibitory influence of spontaneous basal 
release and agonist-stimulated release of EDRF. For example, in rat aorta 
contractile responses to some a-adrenoceptor agonists, particularly partial 
agonists such as clonidine, are sometimes found to be markedly potentiated by 
disruption of the endothelium, while other agonists, particularly those with greater 
intrinsic activity such as phenylephrine, are relatively unaffected 
(EglemQ etal, 1984). However, in an essentially similar study, Martin and 
co-workers (1986) found qualitatively similar but quantitatively different results 
where endothelial removal had less effect versus clonidine but more versus 
phenylephrine. Mechanical removal of the endothelium in the rat isolated 
thoracic aorta is associated with an increase in the maximum contraction to 
phenylephrine and an increase in both the maximum response and potency of 
various partial agonists at a-adrenoceptors (e.g. clonidine, BHT-920) (Lues & 
Schumann, 1984; Godfraind eta l., 1985).
Young and Vatner (1986) demonstrated that removal of the endothelium not only 
reversed the vasodilator response to adrenaline to vasoconstriction, in the 
conscious animal, but that it also enhanced a  j-adrenoceptor constriction in 
response to phenylephrine and noradrenaline but not to a  2-adrenoceptor 
stimulation with B-HT920. Removal of the endothelium in canine pulmonary and 
systemic blood vessels caused a shift to the left of the concentration-response 
curves to adrenaline, noradrenaline and the a 2-adrenoceptor agonist UK-14304, 
but not of that to the selective aj-adrenoceptor agonist phenylephrine (Miller & 
Vanhoutte, 1985). Endothelial disruption was associated with an enhancement of 
contractile responses to NA, without a similar effect on responses to BHT-920 
(McGrath et al, 1990).
Initial experiments showed an unexpected series of effects from the supposedly 
selective a 2-adrenoceptor agonist UK-14304 which we pursued and which
20
eventually turned out to be due to the very effective a  \-adrenoceptor system in 
this artery rather than an involvement with c^-adrenoceptors.
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Section 2: Methods and Materials
2.2.1 Methods
Common carotid arteries (700 pm in lumen diameter) were obtained from male 
Wistar rats, weighing 320-400g, which were killed (i.p. injection) by overdose 
with pentobarbitone sodium. Although carotid artery is smaller than aorta a pair 
of common carotid arteries were easily dissected out and were placed in cold, 
oxygenated modified Krebs-Henselite solution (Krebs). The arteries were cleared 
of any extraneous connective tissue using fine scissors, when it was necessary 
under a dissecting microscope.
Each preparation was cut transversely in to 3-4mm rings and suspended between 
thick wire supports. During the preparation of the arterial ring segments, any 
contact with the luminal surfaces was avoided to preserve endothelial integrity. In 
some preparations the endothelial layer was removed mechanically by gently 
rolling the tissue around a thin wire. Removal of the endothelium was confirmed 
pharm acologically by a lack of relaxant response to the potent 
endothelium-dependent vasodilator acetylcholine. This ensured that endothelium 
removal had been successful. Fluorescent dyes were also used to examine 
histologically the structure of rubbed endothelial cells in some random 
preparations (Daly et al., 1992). Each ring was suspended horizontally by means 
of two stainless-steel L-shaped hooks carefully passed through the lumen. The 
upper support was connected by cotton to an isometric transducer while the lower 
support was connected to a glass tissue holder. The arterial rings were mounted in
o
10ml isolated organ bath, bathed in Krebs maintained at 37 C and gassed with 
95% 0 2 plus 5% C 0 2.
The rings were then placed under resting tension at 2.5-3g for each group of 
arterial rings of carotid artery, which was determined from the tension 
development curves to be optimal (Figure 2.1).
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Isometric contractions were measured by a Grass FT03 transducer connected to a 
Linseis (TYP 7208) pen recorder. In all experiments, tissues were left to 
equilibrate for a 60 min period, during which time the tension was re-adjusted to a 
set value which was maintained constant throughout the rest of the experimental 
day. Each preparation was then exposed to NA (lfiM) and allowed to contract for 
5-10 min. This first contraction to an agonist minimises changes in the sensitivity 
of preparations to further addition of agonists. Following complete washout, an 
additional one hour equilibration period was allowed before commencement of 
any other experimental procedure
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Figure 2.1
Tension-development curves of the effects of resting tension on active contractile 
force of the rat isolated common carotid artery in response to KCI (50mM) or NA 
(ljj-M). Optimal contractile force is demonstrated with resting tension of (2.5-3g) 
in all groups of arterial rings.
Each point or column represents mean ± s.e.mean (n=10).
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2.2.2 Protocol
Concentration-response curves were constructed in a cumulative manner by 
increasing the concentration of the agonists in half-log increments. When 
responses to agonists were not maintained, addition of the next concentration was 
made as close to the peak as possible. An initial control CCRC, to any given 
agonist, was obtained in each preparation. Following attainment of the maximal 
control contraction, preparations were washed until complete relaxation was 
effected. The preparations were then left for a further period of 45-60 min before 
re-exposure to the agonist.
When the competitive antagonists like prazosin and rauwolscine were used, the 
preparations were incubated at least for 45 minutes with the drugs prior to the 
onset of a second CCRC.
When examining the effects of angiotensin II and L-NAME (an inhibitor of NO), 
these drugs were added approximately 10-15 min prior to the onset of CCRC to 
an agonist.
2.2.3 Statistical analysis
Results are expressed as mean ± standard error of mean (s.e.mean). Comparisons 
between two groups were performed using the paired or unpaired Student's t-test 
with values as follow: * p<0.05, ** 0.001 <p<0.01, *** p < 0. 001. Comparisons 
among several groups were performed using one-way analysis of variance. A 
value of p <0.05 was taken as statistically significant.
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2.2.4 Calculation of results
Responses to agonists are expressed as a percentage (mean ± s.e.mean) of 
maximum response of the first control CCRC to any given agonist or of the 
maximum response to NA (lpM ) in the first of experiment. The potency of 
agonist was determined as the pD2 , which is the negative logarithm of the 
concentration causing half the maximal response. In examining the effect of 
antagonist, agonist concentration ratio values were determined from the 
concentrations producing 50% of the maximum response (EC50) the absence 
and presence of each concentration of antagonist. The EC50 value of the agonist 
was expressed as the pD2 value which was calculated as the negative logarithm of 
the EC50 value (pD2= -log EC50). Schild analysis (Arunlakshana & Schild, 1959) 
was performed for competitive antagonists where appropriate by plotting log 
(DR-1) on the y-axis (where DR represents the concentration ratio (EC50 (in 
presence of antagonist) divided by EC50 (in absence of antagonist) against the log 
M [antagonist] on the x-axis and fitting using linear regression. The pA2 value 
(-log M [antagonist] required to produce a concentration ratio of 2) was derived 
from the x-intercept which is equal to the antagonist dissociation constant (Kg) 
under equilibrium conditions. If antagonism is competitive a plot of the logarithm 
of dose ratio-1 (DR-1) against the negative logarithm of the molar concentration of 
the antagonist yields a straight line whose slope is not significantly different from 
one. Antagonist was considered to be competitive if the 95% confidence limits 
for the slope of the Schild plot, drawn by linear regression, overlapped unity. 
Concentrations of antagonists which did not consistently produce greater than 
2-fold rightward displacements of the agonist CCRC were excluded from 
quantitative Schild analysis.
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2.2.5 Solutions and Drugs
The composition of the modified Krebs-Henselite solution was as follows: (in 
mM): NaCl 118.4, NaHC03 25, KCI 4.7, KH2P 0 4 1.6, MgSO4 0.6, CaCl2 2.5 
and glucose 11. Na2EDTA (23(iM) was also included in the Krebs in all 
experiments to prevent degradative oxidation of NA and propranolol (lp-M) and 
cocaine hydrochloride (IOjiM) were also included to inhibit P-adrenoceptors and 
neuronal uptake of NA respectively. The following compounds were used:
prazosin HC1 (Pfizer); rauwolscine (Roth); UK-14304 (Pfizer); (-)-phenylephrine 
HC1 (Sigma); (-)-noradrenaline bitrate (Sigma); propranolol HCI (Sigma); cocaine 
HC1 (Mac Carthys); Angiotensin II amide (Ciba); L-NAME (Sigma); L-Arginine 
(Sigma); U-46619 (Upjohn); PGF2a (Upjohn); indomethacin (Sigma); adenosine 
(Sigma); adenosine triphosphate (Sigma); HV-723 ( Gift from Dr. Muramatsu, 
Japan); 5-methylurapidil (Research Biochemicals International); isoprenaline 
(Sigma); acetylcholine (Sigma); WB-4101 (Research Biochemicals International); 
YM-12617 (Yamanouchi); sodium flurbiprofen (Boots); sodium nitroprusside 
(Sigma); 5HT (Sigma); GR-32191B (Glaxo); chloroethylclonidine (Research 
Biochemicals International); BMY-7378 dihydrochloride (Research Biochemicals 
International); Niguldipine (Research Biochemicals International); Delequamine 
(RS-15385-197, Syntex, Gift from Dr. Whiting)
All drugs except U-46619, indomethacin and niguldipine were dissolved in 
distilled water. U-46619 was initially dissolved in high-performance liquid 
chromatography-grade absolute ethanol, with subsequent dilutions made in 
distilled water. Niguldipine was initially dissolved in dimethyl sulphoxide 
(DMSO), with subsequent dilutions made in distilled water. The stock solution of 
indomethacin was dissolved in 10% of NaHC0 3 - Solutions of indomethacin,
sodium nitroprusside and niguldipine were protected from light and experiments
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carried out in near darkness. All concentrations of the drugs used are expressed as 
final concentration in the organ bath.
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Section 3: Results
2.3.1 Potency of agonists
The mixed a-adrenoceptor agonist NA (non-selective), PE (selective a i )  and 
UK-14304 (selective 0C2) produced concentration-dependent contractions in the rat 
isolated common carotid artery. The rank order of potencies for these agonists 
were as follows: NA> PE > UK-14304 (Figure 2.2).
Consecutive CCRC's to NA, PE and UK-14304 were reproducible, there being a 
small and non significant change in the maximum response with time (Figure 2.3).
2.3.2 Effects of aj-adrenoceptor agonists and antagonists
NA produced isometric contraction with a pD2 of 7.97 and a maximum 
contraction of 1.13 ± 0.03g. PE produced isometric contraction with a pD2 of
7.07 and a maximum contraction of 0.96 ± 0.02g. The maximum response to NA 
and PE were not significantly different, but to UK-14304 was smaller than for the 
other two agonists. Relative to NA its intrinsic activity was 0.37. UK-14304 did 
not clearly produce maximum.
Responses to these agonists were analysed using antagonists proposed to be 
selective as follows: prazosin, selective for c.f. 012; 5MU, selective c-f- 
a j B; WB-4101, selective ccia c.f.oc.13 and CEC irreversible antagonist at a jg  c.f. 
aiA  and oti]>
Prazosin produced concentration dependent parallel rightward displacement of 
NA and PE CCRC (Figure 2.4a and 2.4b respectively). The pA2 value for 
prazosin versus NA was 10.05 and the slope of Schild plot was not significantly 
different from one (1.045), indicating competitive antagonism (Table 2.1).
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The pA2 value for prazosin versus PE was 9.81 and slope of the Schild plot was 
very near to unity (0.98), indicating competitive antagonism (see Schild plot 
figures).
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Figure 2.2
Cumulative concentration-response curves to a-adrenoceptor agonists: NA (O ), 
PE (A) and UK-14304 (□) in the rat isolated common carotid artery . Results are 
expressed as: a) % of the maximum response of each individual CCRC to agonist 
or b) % of the maximum response to initial application of NA (lpM ).
Each point represents the mean ± s.e.mean (n=8).
31
a ) 120 - 
|  100-  
I  80-w
E 60 -
40 -o
coo 2 0 -
5 47 681 0 - 9
Log[NA](M)
b )
E
3
E
X(0
E
80 -
60 -
40 -o
20 -
0 A -  
-  1 0
coo
5 49 8 7 6
Log[PE](M)
c )
E 100 -
3
.§ 80 - 
xro _ _
E 60"
40-o
coo
20  -
1 0 9 8 7 6 5 4 3
Log[UK-14304](M)
Figure 2.3
Effect of time on cumulative concentration-response curves to a-adrenoceptor 
agonists a) NA b) PE c) UK-14304, in the rat isolated common carotid artery. 
The first CCRC to agonist is represented by (O ) while second CCRC to agonist 
represented by (■). Results are expressed as: % of the maximum response of the 
first CCRC to each agonist.
i
Each point represents mean ± s.e.mean (n=8).
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pA2 values obtained for the 0 4 -adrenoceptor antagonists using Schild analysis by 
plotting log (DR-1) on the y-axis against the log M [antagonist] on the x-axis and 
fitting using linear regression. The pA2 value was derived from the x-intercept 
which is equal to the antagonist dissociation constant (Kg) under equilibrium 
conditions, a) prazosin b) 5-MU c) WB-4101 d) YM-12617 against contractions 
to noradrenaline in the rat isolated common carotid artery.
Each point represents an individual experiment.
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pA2 values obtained for the ocj-adrenoceptor antagonists using Schild analysis by 
plotting log (DR-1) on the y-axis against the log M [antagonist] on the x-axis and 
fitting using linear regression. The pA2 value was derived from the x-intercept 
which is equal to the antagonist dissociation constant (Kg) under equilibrium 
conditions a) prazosin against contractions to phenylephrine b) BMY-7378 c) 
HV-723 d) rauwolscine against contractions to noradrenaline in the rat isolated 
common carotid artery.
Each point represents an individual experiment.
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Table 2.1
antagonist P^ 2 slope
rauwolscine 6.9 0.72
(6.63-7.2) (0.61-0.84)
prazosin 10.05 1.04
(9.8-10.32) (0.94-1.1)
5MU 9.1 0.57
(8.61-9.61) (0.46-0.69)
YM-12617 9.44 1.02
(9.24-9.64) (0.905-1.15)
WB-4101 10.7 0.62
(10.27-11.15) (0.53-0.71)
HV-723 8.7 1.04
(8.43-9) (0 .8 8 -1 .2 1 )
BMY-7378 9.24 0 .6 8
(8.86-9.4) (0.57-0.78)
List of pA2 values with the slopes of the Schild plots (With 95% confidence 
limits) for a-adrenoceptor antagonists against responses to noradrenaline in the rat 
isolated common carotid artery in the presence of propranolol (l|iM ) and cocaine 
(10|uM).
pA2 values were determined from a regression analysis of the logarithm of dose 
ratio-1 against the negative logarithm of the molar concentration of the antagonist.
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Figure 2.4
Effects of selective a\-adrenoceptor antagonist prazosin O.lnM (□), InM (A) or 
lOnM (■ ) on control responses to a) NA (O ) b) PE ( # )  in the rat isolated 
common carotid artery. Responses are expressed as % of the maximum response 
of the control CCRC to NA or PE in the absence of antagonist.
Each point represents mean ± s.e.mean (n=6-8).
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WB-4101 produced concentration-dependent shifts in the potency of NA without 
reducing the maximum response (Figure 2.5a). The pA2 value for WB-4101 was
10.7 and slope of the Schild plot was 0.62, very different from unity, suggesting 
non-competitive antagonism (Table 2 .1).
5-MU produced concentration-dependent shifts in the potency of NA without 
reducing the maximum response (Figure 2.5b). The pA2 value for 
5-methylurapidil was 9.1 and slope of the Schild plot was 0.57, very different 
from unity, indicating non-competitive antagonism (Table 2 .1).
The irreversible antagonist chloroethylclonidine (100|iM) that preferentially 
alkylates a  \ g-adrenoceptors, failed to reduce significantly the maximum response 
to NA but produced parallel shifts in the potency of NA. The tissues were treated 
with CEC (lOOfiM) for 30 minutes followed by washout of the irreversible 
antagonist for an additional 30-45 minutes. The shift in potency of NA produced 
by CEC was 125.9 times (Figure 2.6a).
HV-723 produced parallel shifts of the concentration-response curve to NA 
without reduction in maximum response (Figure 2.6b). Schild regression analysis 
yielded line with slope of 1.04, not significantly different from one and pA2 value 
of 8.7 (Table 2.1).
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Figure 2.5
Effects of -adrenoceptor antagonists a) WB-4101 InM (□ ), lOnM (A) or 
0.1 (j,M ( # )  b) 5-methylurapidil lOnM (□ ), 0.1 (iM (A) or lp,M (# )  on control 
responses to NA (O ) in the rat isolated common carotid artery. Results are 
expressed as % of the maximum response of the control CCRC in the absence of 
antagonist.
Each point represents mean ± s.e.mean (n=6).
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Figure 2.6
Effects of a) treatment with the alkylating drug chloroethylclonidine (■); tissues 
were treated with lOOpM for 30 minutes followed by washout for an additional 
30-45 minutes, b) aj-adrenoceptor antagonist HV-723 lOnM (□), 0.1 p,M (A) or 
lpM  (# ) , on control responses to NA (O) in the rat isolated common carotid 
artery. Results are expressed as % of the maximum response of the control CCRC 
in the absence of antagonist or chloroethylclonidine.
Each point represents mean ± s.e.mean (n=6).
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The S(+)-isomer of the dihydropyridine Ca2+ channel antagonist, niguldipine 
caused a shift of the concentration-response curve of NA to the right and reduced 
the maximum response. The shift in potency of NA produced by niguldipine was
4.07 times (Figure 2.7a).
The selective a  ^ -adrenoceptor antagonist BMY-7378 produced a parallel shift of 
the concentration-response curve to NA with a large change in maximum response 
(Figure 2.7b). Schild regression analysis yielded a line with a slope of 0.68, and 
pA2 value of 9.24 (Table 2.1).
Increasing concentrations of aj-adrenoceptor antagonist YM-12617 shifted NA 
concentration-response curve to the right in a parallel manner with a large change 
in maximal response (Figure 2.8a). The pA2 value for YM-12617 was 9.44 and 
slope of the Schild plot was 1.02, not different from unity, indicating competitive 
antagonism (Table 2.1).
Increasing concentration of the selective (^-adrenoceptor antagonist rauwolscine 
produced small rightward displacement of NA CCRC on high concentration 
(lfiM) (Figure 2.8b). The pA2 value was 6.9 and slope of the Schild plot was 
0.72, significantly different from unity, indicating non-competitive antagonism 
(Table 2.1).
The rank order of potencies for these a-adrenoceptor antagonists was as follows: 
WB-4101> prazosin> YM-12617> BMY-7378> 5MU> HV-723> rauwolscine 
(Table 2.1).
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Figure 2.7
Effects of a) treatment with the niguldipine (ljxM) ( ■ )  b) selective 
a 1D-adrenoceptor antagonists BMY-7378 InM (□), lOnM (A) or 0.1(iM (■ ) on 
control responses to NA (O) in the rat isolated common carotid artery. Results 
are expressed as % of the maximum response of the control CCRC in the absence 
of antagonist or niguldipine.
Each point represents mean ± s.e.mean (n=6).
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Figure 2.8
Effects of a-adrenoceptor antagonists a) selective ai-adrenoceptor agonist 
YM-12617 InM (■ ), lOnM (A) or O.lpM ( # )  b) selective a 2-adrenoceptor 
antagonist rauwolscine 0.1 |xM (■ ) or l(xM (A) on control responses to NA (O ) 
in the rat isolated common carotid artery. Results are expressed as % of the 
maximum response in the absence of antagonist.
Each point represents mean ± s.e.mean (n=6).
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2.3.3 UK-14304-induced contraction and relaxation
UK-14304 produced isometric contraction with a pD2 of 5.1 and maximum 
contraction of 0.44 ± 0.01 g. Rauwolscine produced a small rightward 
displacement of the UK-14304 CCRC (Figure 2.9a).
Contraction to UK-14304 was inhibited by prazosin (InM, lOnM). Lack of a true 
maximum contraction prohibits a pA2 value for prazosin versus UK-14304, but 
the high sensitivity to prazosin strongly implicates a j  agonism (Figure 2.9b).
Preparations were precontracted with PE (1 jliM) or NA (lfxM) to induce 
contraction. When the contraction reached a plateau, cumulative 
concentration-effect curves to UK-14304 were obtained by increasing its 
concentration in half-log increments (lnM-300|iM). UK-14304 dose-dependently 
induced a relaxation in preparations preconstricted by NA or PE. Versus PE 
(lpM ); PIC50 for UK-14304 was 4.91 ± 0.14 (Figure 2.10a); versus NA (l|aM) 
was 4.75 ± 0.16 (Figure 2.13).
In preconstricted preparations induced by NA, rauwolscine produced relaxation in 
high concentration, PIC50 was 5.76 ± 0.13 (Figure 2.10b).
In preconstricted preparations induced by PE (ljxM), prazosin produced relaxation 
with apICso of 8.14 ± 0.17 (Figure 2.12).
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F igure 2.9
Effects of a) selective a 2-adrenoceptor antagonist rauwolscine 0.1 |iM (□ ) or 
1|J-M (A) and b) selective a\-adrenoceptor antagonist prazosin InM (□) or lOnM 
(A) on control responses to UK-14304 (O) in the rat isolated common carotid 
artery. Responses are expressed as % of the maximum response of the control 
CCRC in the absence of antagonist.
Each point represents mean ± s.e.mean (n=6).
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Figure 2.10
Relaxation effects to a) UK-14304; preconstricted by PE (l|iM ); b) rauwolsine, 
preconstricted by NA (l|iM ); c) UK-14304, preconstricted by PGF2a (l^M ); d) 
UK-14304 (O), or specific thromboxane A2 receptor antagonist, GR-32191B (■) 
preconstricted by U-46619 (0.1 (a,M). Results are expressed as % of maximum 
response to constrictor.
Each point represents the mean ± s.e.mean (n=8).
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Figure 2.11
Cumulative concentration-response curves to the UK-14304 in the absence and 
presence of tone with U46619 (0.1 (iM). Results are expressed as absolute tension 
(g)-
Each point represents the mean ± s.e.mean (n=6).
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Figure 2.12
Relaxation effects of CCRC to ( ■ )  prazosin, (O ) rauwolscine or (□ ) 
delequamine in preparations preconstricted by PE (1 |LtM). Results are expressed 
as % of maximum response to PE (lpM ) used for inducing tone.
Each point represents the mean ± s.e.mean (n=5-6).
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In preconstricted preparations induced by PE (l|xM), selective ot2-adrenoceptor 
antagonist delequamine produced poor relaxation in high concentrations compared 
with rauwolscine (Figure 2.12).
Contrast to a-adrenoceptor agonists, the specific thromboxane A2 receptor 
antagonist, GR-32191B, in preconstricted preparations induced by U-46619 
(0.1 (iM) produced relaxation that PIC50 was 6.5 (Figure 2.10d).
When tone was induced with PGF2a  (1M-M) or U-46619 (0.1 (xM) UK-14304 did 
not produce relaxation but in high concentrations produced contraction (Figure 
2 .10c, d).
Neither functional disruption of the endothelium by rubbing nor inclusion of 
L-NAME (IOOjxM), rauwolscine (ljxM) or flurbiprofen (lfiM) had any effect on 
UK-14304-induced relaxation (Figure 2.13).
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F ig u re  2.13
a) Effects of endothelium removal that preparations have intact endothelium (+E) 
or endothelium removed (-E) b) an inhibitor of NO synthase (L-NAME) IOOjjM 
c) selective ct2-antagonist rauwolscine (lfiM), d) an inhibitor of cyclo-oxygenase 
flurbiprofen (l|iM ) on relaxation of CCRC to a  2 -agonist U K -14304 in 
preconstricted preparations induced by NA (lfiM). Results are expressed as % of 
maximum response to NA (lfiM) used for inducing tone.
Each point represents the mean ± s.e.mean (n=6).
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2.3.4 UK-14304 as an antagonist
The concentration-response curve to PE was shifted in parallel without decreasing 
the maximum response by pretreatment of UK-14304 (3, 10, 30|iM) for 5 or 45 
minutes. The Schild plot of the data yielded a slope of 0.75, which was 
significantly different from unity, suggesting non-competitive antagonism or at 
least, not providing direct evidence of competitive antagonism. pA2 values 
against PE were 5.98 (Figure 2.14a) and 5.89 (figure 2.14b) respectively.
Prazosin caused rightward shifts of PE CCRC. Slope was 0.98 not different from 
unity, indicating competitive antagonism. The pA2 value was 9.81 (see Schild 
plot figures).
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Figure 2.14
Effect of incubation time on the ability of UK-14304 to antagonise PE 3pM (□ ), 
lOpM (A) or 30pM (■ ). UK-14304 was added either a) 5 minutes o rb )  45 
minutes before starting CCRC to PE (O). Responses are expressed as % of the 
maximum response of the control CCRC to PE in the absence of UK-14304.
Each point represents the mean ± s.e.mean (n=6).
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2.3.5 Effects of (L-NAME) on responses to a-adrenoceptor agonists
L-NAME itself in unrubbed preparations caused a large sustained increase in 
vascular tone that was 58 ± 9.5% of the contraction to NA (lpM).
Inclusion of L-NAME (IOOjiM) resulted in small reduction of the "maximum” 
response to NA (Figure 2.16a). pD2 was not changed significantly 8.07 compared 
with 7.89 (Table 2.2).
Inclusion of L-NAME (100|iM) resulted in increase of the maximum response and 
sensitivity to PE (Figure 2.16b). pD2 increased significantly to 8.02 compared 
with 7.03 (p<0.05) (Table 2.2).
Figure (2.16c) shows the effect of L-NAME on response to UK-14304. It 
increased the potency of UK-14304 as well as increasing the maximum tension 
that it was able to achieve in these vessels by 336% of control absolute maximum 
tensions. pD2 increased to 6.63 compared with 5.06 (p<0.01) (Table 2.2).
Surprisingly, mechanical disruption of the vascular endothelium (to an extent 
which prevented vasodilation by an agonist acting via the endothelium-derived 
nitric oxide system) reduced, but did not abolish the ability of L-NAME to 
produce contraction. Addition of L-NAME to rubbed preparations produced a 
significantly smaller contraction than in unrubbed (20 ± 6 % of NA l|iM).
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Figure 2.15
Representative trace recording of inclusion of L-NAME (100[xM) on the isolated 
rat common carotid artery in unrubbed preparations. First the preparations were 
placed under resting tension at 2.5-3g for each group of arterial rings of carotid 
artery. Then tissues were left to equilibrate for a 60 min period, during which 
time the tension was re-adjusted to a set value which was maintained constant 
throughout the rest of the experimental day. L-NAME was added to inhibit NO 
synthase and in these preparations produced contraction.
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Figure 2.16
Effects of L-NAME (100|iM) (■ ) in the preparations with intact endothelium on 
control (O) CCRC to a-adrenoceptor agonists, a) NA b) PE c) UK-14304 in the 
rat isolated common carotid artery. Results are expressed as tension (g).
Each point represents mean ± s.e.mean (n=10). Statistically significant 
differences are represented by * p<0.05, ** 0.001<p<0.01, *** p< 0.001, paired 
Student's t-test. Value of p shows comparison of two curves by one way 
ANOVA.
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2.3.6 Effects of endothelium removal on a-adrenoceptor agonists
In some preparations the endothelial layer was removed mechanically by gently 
rolling the tissue around a thin wire. Removing the endothelium increased 
responses to NA at low concentrations, but the maximum response was not 
changed (Figure 2.17a). pD2 increased to 8 .6 8  compared with 7.85 (p<0.05) 
(Table 2.3).
Removing the endothelium increased responses to PE at low concentrations 
(Figure 2.17b). pD2 increased to 7.83 compared with 7.1 (p<0.05) (Table 2.3).
In preparations with rubbed endothelium maximum response to UK-14304 
increased (Figure 2.17c). pD2 increased to 5.76 compared with 5.06 (p<0.05) 
(Table 2.3).
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Figure 2.17
Effects of removing the endothelium (■) on cumulative concentration-response 
curves to the a-adrenoceptor agonists in preparations with endothelium (O ) a) 
NA b) PE c) UK-14304 in the rat isolated common carotid artery. Results are 
expressed as tension (g).
Each point represents mean ± s.e.mean (n=10). Statistically significant 
differences are represented by * p<0.05, ** 0.001<p<0.01, unpaired Student's 
t-test. Value of p shows comparison of two curves by one way ANOVA.
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Table 2.2
The effect of N^-nitro-L-arginine methylester (L-NAME) on responses to 
a-adrenoceptor agonists in the rat isolated common carotid artery
Agonist Effect of 
L-NAME
Pl>2 n Maximum 
response (g
Noradrenaline Control 7.89 ±0.11 12 1.13 ±0.035
+ L-NAME 8.07 + 0.1 12 0.88 ± 0.024
Phenylephrine Control 7.03 ± 0.09 10 0.98 ±0.021
+ L-NAME 8 .0 2  ± 0.1 * 10 1.15 ±0.014
UK-14304 Control 5.06± 0.08 12 0.44 ±0.018
+ L-NAME 6.63 ±0.12 12 1.45 ±0.08
pD2 is expressed as the -log of the EC50 (concentration producing 50% of the 
maximum response), n shows the number of animals. Data are expressed as 
mean ± s.e.mean. Statistical comparisons with controls were carried out using 
paired Student’s t test., * p<0.05, ** 0.001<p<0.01, *** p<0.001.
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Table 2.3
The effect of mechanical disruption of the vascular endothelium on responses to 
a-adrenoceptor agonists in the rat isolated common carotid artery
Agonist Endothelium pD2  n Maximum
response (g)
Noradrenaline Present 7.85 ±0.14 8 1.1 ± 0 .01
Absent 8 .6 8  ± 0.1  * 8 1 ± 0.03
Phenylephrine Present 7.1 ±0.06 8 0.96 ±0.013
Absent 7.83 ±0.04 * 8 1 ± 0 .0 2 1
UK-14304 Present 5.18 ±0.07 8 0.41 ±0.03
Absent 5.76 ±0.09 * 8 0.62 ± 0.052
**
pD2 is expressed as the -log of the EC50 (concentration producing 50% of the 
maximum response), n shows the number of animals. Data are expressed as 
mean ± s.e.mean. Statistical comparisons with controls were carried out using 
unpaired Student's t test., *<p<0.05, ** 0.001<p<0.01.
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2.3.7 Effect of inducing tone with KC1, PE, U-46619 or 5HT on 
responses to UK-14304
Since L-NAME greatly potentiates responses to UK-14304, a series of 
experiments were conducted to see whether other stimuli that produces 
submaximal contraction would have a similar synergistic effect.
2.3.8 KC1
KC1 (10-15mM) produced a contraction, equivalent to 32 ± 6.4% of the NA 
contraction (1 pM) in each preparation. There was a significant leftward shift and 
increase in maximum response in the CCRC to UK-14304 in the presence of tone 
with KC1 (10-15mM) (p<0.01) (Figure 2.18a).
2.3.9 Phenylephrine
A low concentration of phenylephrine (lOnM) produced a sustained contraction 
equivalent to 16.8 ± 3.3 % of the NA contraction (lpM ). After inducing tone, 
exposure of the preparation to UK-14304, resulted in concentration dependent 
contractions to this agonist. The sensitivity and maximum response of the 
preparation to UK-14304 were not changed (Figure 2.18b).
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Figure 2.18
Effects of inducing tone a) with KCL (10-15mM) b) with 5HT (0.5-1 piM), PE 
(lOnM) or U-46619 (InM ) c) effect of presence of angiotensin All (lOnM) on 
responses to UK-14304 in rat isolated common carotid artery. Results are 
expressed as tension (g).
Each point represents the mean ± s.e.mean (n=6 -8 ). Statistically significant 
differences are represented by *p<0.05, **0.001<p<0.01, using paired Student's 
t-test. Value of p shows comparison of two curves by one way ANOVA.
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2.3.10 U-46619
The thromboxane A2 mimetic agent, U-46619 (InM) produced a sustained 
contraction, equivalent to 17.19 ± 6.14% of the NA contraction (lpM ) in the rat 
isolated carotid artery. In the presence of U-46619, the sensitivity and maximum 
response of the preparation to UK-14304 were not changed (Figure 2.18b).
2.3.11 5-Hydroxytryptamine (5HT)
5HT (0.5-1 pM) produced a contraction equivalent to 22.4 ± 5.4% of NA 
contraction (l|xM). Inducing tone with this agent was not associated with a 
significant enhancement or uncovering of responses to UK-14304 (Figure 2.18b).
2.3.12 Effects of All on responses to UK-14304
All (O.OljxM) produced a transient contraction, which returned to baseline after 
5-10 min, in the rat isolated common carotid artery. This response was equivalent 
to 97 ± 3.23% of NA contraction (ljxM) in each preparation. There was a small 
but significant leftward shift in the CCRC to ot2-adrenoceptor agonist UK-14304 
in the presence of All (p<0.05) (Figure 2.18c).
2.3.13 UK-14304 mediated contraction in present of All or L-NAME is
ctl
Since either L-NAME or All could potentiate the contractile effect of UK-14304, 
the a-adrenoceptor antagonists prazosin and rauwolscine were re-examined to see 
whether UK-14304's main action remained via a j.
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Figure 2.19 shows the effects of rauwolscine (1|liM ), prazosin (1, lOnM) or 
delequamine (lpM ) on the concentration-response curves to UK-14304 in 
preparations pretreated with L-NAME. Rauwolscine produced a small shift in the 
UK-14304 concentration-response curve. This was a surmountable antagonism 
with no shift in maximum. It was however characterised by a shallower CCRC 
which contrasted with the parallel shifts produced by prazosin (Figure 19). 
Delequamine did not significantly altered the pD2 for UK-14304. However the 
maximum response was increased. The results show that responses to UK-14304 
in the presence of L-NAME were rauwolscine- and delequamine-resistant but 
prazosin-sensitive in this artery.
In the presence of prazosin (lOnM) and AH (lOnM), responses to UK-14304 were 
not significantly different from preparations that had prazosin alone although there 
was a tendency to increase. By adding rauwolscine (ljaM) in tissues that had 
prazosin (lOnM) and All (lOnM), the concentration-response curve to UK-14304 
had a small shift to the left (Figure 2.20). This is similar to the situation without 
AH or in the presence of L-NAME (see Figure 2.19).
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Figure 2.19
Analysis of a-adrenoceptor contractile response to UK-14304 after potentiation 
with L-NAME (100pM). Responses are expressed as % of the maximum 
response of the control CCRC to UK-14304 in the presence of L-NAME. 
Concentration is shown as Log(M) in the graphs.
Each point represents mean ± s.e.mean (n=6 ).
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Figure 2.20
Analysis of a-adrenoceptor contractile response to UK-14304 after potentiation 
with All (lOnM) and in presence of prazosin or rauwolscine on responses to 
UK-14304. Responses are expressed as % of the maximum response of the 
control CCRC to UK-14304 in the absence of antagonist or AIL Concentration is 
shown as Log(M) in the graphs.
Each point represents mean ± s.e.mean (n=6).
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2.3.14 Relaxations to ACh, ATP, adenosine or isoprenaline
ACh relaxed preparations with intact endothelium. The maximum relaxation was 
59% of NA (lpM ) induced tone and PIC50 was 7.04. Treatment with L-NAME 
(lOOpM) 10-15 minutes prior to ACh abolished any relaxation to ACh. In 
preparations without endothelium there was no relaxation in response to ACh 
(Figure 2.21a).
Isoprenaline relaxed preparations both with and without endothelium. Maximum 
relaxations were 55.72% and 52.41% of U-46619 (0.1 pM) induced tone in 
unrubbed and rubbed preparations respectively. PIC50 values were 6.95 and 6 .8 8  
in tissues with endothelium and without endothelium respectively. Since the 
relaxation was not affected significantly by removal of the endothelium, this 
suggests that relaxation was due to stimulation (3-adrenoceptors located on the 
smooth muscle cells (Figure 2.21b).
Adenosine and ATP both produced relaxations versus NA (lpM ), but in high 
concentrations. For adenosine the PIC50 value was 4.15 with endothelium, 3.98 
without (not significantly different) (Figure 2.21c).
For ATP PIC50 value was 3.97 with endothelium, without 3.82 (not significantly 
different) (Figure 2.2Id).
It is likely that relaxations to ATP and adenosine in rat carotid artery were largely 
due to stimulation of purinoceptors located on the smooth muscle cells not on the 
endothelium.
5HT produced isometric contraction with a pD2 of 5.82 and a maximum 
contraction of 0.57 ± 0.07g (Figure 2.22).
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Figure 2.21
Relaxation effects of endothelium-dependent or independent agonists. 
Preparations have intact endothelium (+E) or endothelium removed (-E) by gently 
rolling the tissue around a thin wire a) ACh, also with endothelium but in 
presence of L-NAME (lOOpM); preconstricted by NA (l|iM ) b) P-adrenoceptor 
agonist isoprenaline preconstricted by U-46619 (0.1 pM) c) and d) adenosine or 
ATP respectively preconstricted by NA (lpM ). Results are expressed as % of 
maximum response to constrictor.
Each point represents the mean ± s.e.mean (n=8). Statistically significant 
differences are represented by * p<0.05, *** p< 0.001, paired (effect of L-NAME) 
or unpaired (effect of adenosine) Student's t-test. Value of p shows comparison of 
two curves by one way ANOVA.
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Figure 2.22
Cumulative concentration-response curves to 5HT (O) in the rat isolated common 
carotid artery . Results are expressed as: a) % of the maximum response of CCRC 
to agonist or b) % of the maximum response to NA (lpM ) in the first of 
experiment.
Each point represents the mean ± s.e.mean (n=5).
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Section 4: Discussion
Our study demonstrates that in the rat common carotid artery: i) the population of 
postjunctional a-adrenoceptors mediating contraction of smooth muscle is ii) 
the subtype o f a  j-adrenoceptor mediating contraction is n o n - a ^ - ,  non 
a  1 3 -adrenoceptor . iii) UK-14304 is an a  1-adrenoceptor partial agonist.
2.4.1 Contractions to a-adrenoceptor agonists are mediated by 
ai-adrenoceptors
It has been difficult to demonstrate contraction to postjunctional a 2-adrenoceptors 
in isolated large arteries. The present study clearly shows dominance of 
a  1-adrenoceptors. Although there are a few old reports of the presence of a i  -and 
a 2~adrenoceptors in arterial preparations and a  2-adrenoceptors in the veins 
(Ruffolo, 1986), our finding of a  1-adrenoceptors in this large artery is consistent 
with most of the intervening literature.
It has long been known that phenylephrine is a relatively selective 
a  1-adrenoceptor agonist c.f. a 2 (Starke et a l , 1975) and that prazosin is a highly 
selective a  1-adrenoceptor antagonist with a more than 250 times higher affinity 
for the a  1-adrenoceptor than for the a 2-adrenoceptor (McGrath & Daly, 1995). In 
this study contractions to NA and PE were relatively sensitive to low 
concentrations of prazosin (InM). Responses to NA were insensitive to the 
selective a  2 antagonist rauwolscine. In high concentration rauwolscine (lpM ) 
caused only a small shift to the right of the NA CRC.
UK-14304 is a selective a 2-adrenoceptor agonist in a variety of preparations 
(Cambridge, 1981). UK-14304 produced a concentration-dependent contraction 
with a maximum 41.3 ± 4.47% of NA (lpM). In high concentration rauwolscine 
(1 |l iM )  caused only a small shift on responses mediated by UK-14304.
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2.4.2 Subtype of a-adrenoceptor mediating contraction is non-ai^-, 
non aiB-adrenoceptor
Affinity constants (pKb) for prazosin in various tissues can be roughly subdivided 
into two groups. One with high pKg values close to 10 ( a ^ ) ,  another with lower 
values less than 9, a —^ Muramatsu et al,. 1990). Since the pA2 value for prazosin 
in this preparation is 10.05, this indicates subtype.
The a iA _adrenoceptor subtype shows high affinity for WB-4101 and 
5-methylurapidil and is relatively insensitive to the alkylating agent, 
chloroethylclonidine, while the a  ^ -adrenoceptor subtype has low affinity for the 
antagonists mentioned above and is potently inactivated by CEC. Both - and 
ajB-adrenoceptor subtypes have a high affinity for non-subtype selective 
antagonist prazosin (Han et al., 1987a). 5-methylurapidil is highly selective (50- 
to 100-fold) but WB-4101 show less selectivity (10- to 20-fold) for 
a  i A-adrenoceptor subtype overajB (Hanft & Gross, 1989).
In our study in addition to prazosin, all a —antagonists that were used (5-MU, 
WB-4101, HV-723, YM-12617 and BMY-7378) showed high potency. The slope 
of Schild plots for prazosin was near to unity.
The S(+)-isomer of the dihydropyridine-type Ca2+ channel antagonist, niguldipine 
is the most selective ligand available for the aiA-adrenoceptor subtype. It is at 
least 50- to 100-fold selective for the a^-adrenoceptor over aig-adrenoceptor 
subtype (Boer et al., 1989). Niguldipine produced a shift of the concentration- 
response curve of NA to the right and reduced the maximum response (50%). 
The shift in potency of NA produced by a high concentration of niguldipine 
(lpM ) was 4.07 times.
The a^-adrenoceptor subtype is considered insensitive to the alkylating agent, 
chloroethylclonidine which is a reactive derivative of clonidine, but in this study
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CEC produced a parallel shift in the potency of NA. Together these observations 
suggest that contractions of the rat common carotid artery are not mediated by 
ocia. In ra* vas deferens, the competitive antagonists prazosin, WB-4101 and 
5MU inhibited contractions to NA with pA2  values of 9.26, 9.54, and 8.43 
respectively. CEC (lOOpM) failed to affect contractions to NA. It was 
concluded that contractions of rat vas deferens are mediated by a j^ -  
adrenoceptors as shown by the high potency of a  i^-adrenoceptor selective 
antagonists and the lack of effect of CEC (Aboud et al, 1993).
CEC has been classified as a selective, irreversible a  1 3 -adrenoceptor antagonist 
(Minneman, 1988) and has been used to subdivide aj-adrenoceptor subtypes. 
CEC did not reduce the maximum response to NA, but produced a parallel shift in 
the potency of NA. While the a  1 3 -adrenoceptor subtype has low affinity for the 
WB-4101 and 5MU, it is potently inactivated by CEC. In rat spleen, the 
competitive antagonists prazosin, WB-4101 and 5MU inhibited contractions to PE 
with pA2 values of 9.56, 8.85, and 6.62 respectively. CEC (lOOpM) significantly 
reduced the maximum contraction to PE. Contractions of rat spleen are mediated 
by a  1 3 -adrenoceptors since a  ^-selective antagonists showed low potency and 
CEC significantly reduced the maximum response to PE (Aboud et al., 1993).
The cloned a  1 3 -adrenoceptor, characterised by its low affinity for 
5-methylurapidil, oxymetazoline and (+)-niguldipine and its relative resistance to 
alkylation by CEC, is without a clear-cut functional correlate (Ford et al., 1994). 
BMY-7378, is a selective a  1 3 -adrenoceptor antagonist (Saussy et a l , 1994).
In the classical a  1 -adrenoceptor preparation, rat aorta, the potencies of WB-4101 
and 5-MU against contractions to noradrenaline in rat aorta were 9.21 and 8.12 
respectively. CEC (IOOjjM) shifted potency of CCRC to NA 26.1 times. CEC 
did not reduce the maximum response and the shift in potency of NA was parallel. 
They concluded that the subtype of a  1 -adrenoceptor have may represent
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functional a  i£> (Aboud et al., 1993). Affinity estimates for a  j-adrenoceptor 
ligands prazosin, WB-4101, 5-MU and S(+)-niguldipine were 9.9, 9.6, 8 and 7.1 
respectively at rat cloned a  ^ -adrenoceptor (Clarke et a l, 1995).
In this study the selective a  1D-adrenoceptor antagonist BMY-7378 produced 
parallel shift of concentration-response curve to NA with a pA2 value of 9.24, 
very near to the value obtained in rat aorta. In functional assays using rat aorta, 
the phenylephrine-induced increase in tension was inhibited in a competitive 
manner by selective aip-adrenoceptor antagonist BMY-7378 with apA 2 value of
9.1 (Saussy et al., 1994).
Comparison of pA2 values for the antagonists with their published pKj on cloned 
subtypes (Burt etal., 1995).
pKj on cloned a  i-adrenoceptors 
expressed in cells
antagonist a lb a la a ld ra t carotid
artery
prazosin 9.6 ±0.2 9.2 ±0.2 9.4 ±0.2 10.05
WB-4101 8.2 ±0.1 9.5 ±0.3 9.2 ±0.1 10.7
5-MU 6 .8  ±0.3 8 .8  ±0.1 7.3 ±0.3 9.1
BMY-7378 7.2 6 .6  9.4 9.24
Taken together, these data suggest that contractions of the rat common carotid 
artery are mediated by non-oq non-oqg-adrenoceptors, due to the high potency 
of the a  1A-selective antagonists and sensitivity to CEC. The pA2 values 
correlated best with the published affinities of these compounds on the expressed
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ajj-adrenoceptor clone and poorly with those at either the expressed a  u,- or 
a  i a-adrenoceptor clones.
Functional potencies on rat aorta and common carotid artery (pA2/pKB) and 
binding affinities (pKj) to cloned a 1(j adrenoceptors also suggest a  id  for rat 
carotid artery.
antagonist aid binding rat aorta rat
artery
prazosin 9.5 ±0.1 9.8 ±0.2 10.05
WB-4101 9.2 ± 0.06 8.9 ± .08 10.7
5-MU 7.8 ±0.03 7.8 ±0.19 9.1
BMY-7378 8 .2  ± 0.1 8.3 ±0.1 9.24
The effect of BMY-7378 suggests a functional a i D-adrenoceptor such as was 
reported in rat aorta (Perez et a l, 1991; Saussy et al, 1994), perhaps with the 
presence of at higher concentrations of noradrenaline of a receptor with relatively 
low affinity for the antagonists.
2.4.3 Analysis of the vasorelaxation produced by UK-14304
It is well-known that stimulation of postsynaptic (^-adrenoceptors can initiate not 
only a vasoconstriction (Van Meel et al., 1981; McGrath, 1982) but also a 
relaxation (Cocks & Angus, 1983; Miller & Vanhoutte, 1985; Angus etal., 1986). 
In the present study, our initial observations showed that UK-14304 induced 
relaxation in isolated rat common carotid artery preconstricted by NA or PE 
which would have been consistent with a 2-adrenoceptors-mediated stimulation of 
endothelial cells leading to a relaxation of the artery. However UK-14304
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-induced relaxation was not influenced by the absence of the endothelium or 
inclusion of L-NAME (lOOpM).
It quickly became apparent that a UK-14304-induced relaxation of NA-induced 
tone was independent of endothelium and due to its occupation of some 
a  i-adrenoceptors. However a number of possible a  \ -mediated actions also has to 
be excluded since we are seeking as complete as possible an analysis of 
a-adrenoceptor-mediated actions in this vessel.
Furthermore UK-14304-induced relaxation was not inhibited by the selective 
ot2-adrenoceptor antagonist rauwolscine. Rauwolscine has been shown to be a 
selective ct2-antagonist (Weitzell et al., 1979) and has been used widely as an 
a.2 -antagonist in assessing a j -  and a  2-adrenoceptor-mediated contractile 
functions and adrenoceptor properties in vascular smooth muscle (McGrath, 
1982). The present study indicates that UK-14304 induced relaxation is not 
mediated by activation of ot2-adrenoceptors in the rat common carotid artery.
UK-14304-induced relaxation was not modified by flurbiprofen (lpM ) which 
inhibits cyclo-oxygenase. Therefore relaxation does not involve PGI2 .
Since propranolol (lpM ) was always present in the Krebs, UK-14304-induced 
relaxation was not mediated by P-adrenoceptors.
In preparations preconstricted by PGF2a or U-46619, UK-14304 did not induce 
any relaxation but rather in high concentration produced contraction. When tone 
was raised with U-46619 (0.1 pM), the specific thromboxane A2 receptor 
antagonist, GR-32191B produced relaxation.
In the present study UK-14304 dose-dependently induced relaxation in 
preparations preconstricted by NA or PE but not in those preconstricted by PGF2a 
or U46619. This suggests that UK-14304 acts by antagonism of 
a!-adrenoceptors. Known antagonists produce similar effects. Both prazosin and
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rauwolscine dose-dependently induced relaxation in preparations preconstricted 
by PE or NA. Rauwolscine like prazosin produced relaxation, but in high 
concentrations, consistent with blocking of a  j-adrenoceptors. The selective 
(X2-adrenoceptor antagonist delequamine (Brown et al., 1993) produced a small 
relaxation compared to rauwolscine, consistent with its greater selectivity for 
a 2-adrenoceptors.
Concentration-dependent relaxation versus phenylephrine (l|iM ) yielded a PIC50 
for of UK-41304 4.91 ± 0.14, for prazosin 8.14 ± 0.21 and for rauwolscine versus 
NAwas 5.76 ±0.13.
When tested as an antagonist UK-14304 produced parallel shifts of 
concentration-response curves to PE. Slope of the Schild plot was different from 
unity so purely competitive antagonism can not be established. However, since 
UK-14304 does produce contraction, evidence for competitive antagonism may 
be unrealistic.
These results with prazosin, rauwolscine and GR-32191B clearly show when tone 
is induced by an agonist, antagonist activity of a compound can produce 
relaxation by antagonism of receptors occupied with agonist. Therefore, it is 
likely that UK-14304-induced relaxation in preparations preconstricted by NA or 
PE is due to its antagonistic action against activated a  1-adrenoceptors. 
Previously, a 2-adrenoceptor agonists have been reported to behave as antagonists 
at a  1 -adrenoceptors in the isolated and perfused hindquarter of the rat (Kobinger 
& Pichler, 1983 ) and in rabbit aorta (Lues & Schumann, 1984).
There was no evidence from our study that a 2-adrenoceptors can mediate the 
release of EDRF in rat carotid artery. This is consistent with attempts to induce 
endothelium-dependent relaxation in rat aorta after blockade of a  j-adrenoceptors 
by prazosin, in which clonidine failed to cause relaxation (Godfraind et al., 1985; 
Martin et al., 1986). Furthermore, no 0*2 binding sites could be detected on the rat
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aortic smooth muscle or its endothelium by use of [H ]-rauwolscine binding 
combined with autoradiography (Jacobs & Dashwood, 1986).
2.4.4 Influence of endothelium removal and L-NAME
The contribution of NO to the regulation of vascular tone in rat common carotid 
artery has been demonstrated by showing that inhibition of its synthesis by 
L-NAME results in significant vasoconstriction. Also, L-NAME prevented the 
relaxation of rat carotid artery by endothelium-dependent vasodilator 
acetylcholine. As reported by Rees and co-workers (1989) inhibition of NO can 
induce an endothelium-dependent and enantiomerically specific contraction of the 
vascular rings, confirming that there is a continuous use of L-arginine for the 
basal release of NO. The magnitude of this basal release can be determined 
indirectly by measuring the degree of contraction. In our study L-arginine 
(300|jM), which is a substrate for EDRF (Palmer et al, 1988), totally reversed the 
effects of L-NAME. L-arginine had no effect on its own (unpublished data).
Mechanical disruption of the vascular endothelium (to an extent which prevented 
vasodilation by an agonist acting via the endothelium-derived nitric oxide system) 
reduced, but did not abolish the ability of L-NAME to produce contraction. This 
suggests an extra-endothelial site for nitric oxide synthesis in rat common carotid 
artery. One site could be the vascular smooth muscle cell, as already suggested 
for rat ileac artery and rabbit pulmonary artery (Gonzalez et al, 1992; Maclean et 
a l,  1993b). In rabbit pulmonary artery removal of the vascular endothelium 
increased the maximum contractile responses to electrical field-stimulation (EFS) 
but did not inhibit the ability of L-NAME to potentiate contractile responses to 
EFS. Other sites of synthesis could be cells in the adventitia.
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In the present study, the effect of UK-14304 was significantly enhanced in the 
presence of L-NAME. Mechanical disruption of the vascular endothelium 
mimicked the effect of L-NAME on contractile responses to UK-14304 and PE 
consistent with L-NAME inhibiting endothelium-derived nitric oxide synthase. In 
agreement with this study, Joly and co-workers (1992) found that removal of the 
endothelium either by balloon catheter or mechanically by a small metal wire in 
rat carotid artery results in an increase of the contractions evoked by 
phenylephrine.
The results show that inhibition of nitric oxide synthase with L-NAME potentiates 
responses to PE and UK-14304 in rat common carotid artery. In the case of NA 
the result was less clear out. Although L-NAME did not increase sensitivity to 
NA, mechanical disruption increases potency of NA without effect on maximum 
response. The vascular endothelium produces and releases many other factors 
such as the relaxant prostacyclin (Moncada et al., 1978) and contractile factor 
endothelin (Yanagisawa et al.t 1988). As the response to NA was augmented by 
endothelium disruption, but not by L-NAME this could imply an endothelial cell 
derived vasoactive factors other than NO also exert effects on the adrenoceptor 
activation.
The endothelium-mediated depression of the responses is likely to be due to the 
basal release of endothelium-derived nitric oxide by the endothelial cells. It was 
concluded that constitutive NO activity has substantial inhibitory influence on 
vasoconstrictor responses to PE and UK-14304 but not to NA. This effect of 
L-NAME on NA is in contrast to other reports in some other vessels (Thompson 
& Weiner, 1993; Maclean et al., 1993a). The link between L-NAME and 
noradrenaline-induced contraction is unexplained and requires further 
investigation. The reason for this discrepancy is unclear.
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Quantitative differences in the effectiveness of endothelium removal and 
NO-inhibition in various isolated blood vessels on a-adrenoceptors can arise from 
a variety of factors, e.g. a concomitant stimulatory action of these factors on the 
smooth muscle, the release of different endothelium-dependent vasoconstrictor 
substances and the release of different endothelium-dependent vasodilator 
substances.
2.4.5 Effects of contractile agents on responses to UK-14304
Attempts to potentiate responses to UK-14304 with synergistic agents showed: i) 
KC1 increased responses significantly; ii) A ll increased responses though less 
than KC1; iii) inducing tone with PE, U-46619 and 5HT had no effect on 
responses to UK-14304.
Since the original demonstration of postjunctional cc2 -adrenoceptors in the pithed 
rat (Drew & Whiting, 1979; Docherty et al., 1979), identification of this subtype 
in isolated vascular preparations, (i.e.) responding to NA and resistant to prazosin 
or a suitable a!-adrenoceptor antagonist, has proved very difficult. It has been 
reported that activation with a physiological stimulant, namely AH, reveals a 
quiescent population of a  2 -adrenoceptors in the saphenous artery although the 
response was mediated entirely by a  j-adrenoceptors in the absence of AIL This 
is associated with a marked increase in the sensitivity of the preparation (up to 
300 fold) to the a  2 -adrenoceptor agonist UK-14304 (Dunn et al., 1989). 
Similarly, in the perfused isolated tail of the rat a  2 -adrenoceptor-mediated 
responses are observed only after raising tone with, for example vasopressin or 
endothelin (Templeton et al., 1989; Maclean & McGrath, 1990). Similarly, 
phenylephrine-induced tone has been shown to uncover responses to B-HT920 in 
the canine portal vein (Furuta, 1988). Furthermore, ot2 -adrenoceptor-mediated
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responses to BHT-920 in the plantaris artery of the dog are only apparent in the 
presence of Bay K-8644 (Sulpizio & Hieble, 1987).
In the present study activation of isolated common carotid artery with AH 
(lOnM), caused a small but significant increase in the sensitivity of the 
preparation to UK-14304. However, analysis using antagonists showed that 
responses to UK-14304 after potentiation by L-NAME or angiotensin were 
prazosin-sensitive, rauwolscine-resistant, and therefore by definition 
a  i-adrenoceptor-mediated. This is in contrast to earlier studies in which inducing 
tone with phenylephrine or endothelin introduced rauwolscine-sensitive responses 
to UK-14304 in the isolated vascular bed of rat tail (Templeton et a l., 1989; 
Maclean & McGrath, 1990). In the saphenous artery under normal circumstances 
stimulation of postjunctional ai-adrenoceptors provide the positive input required 
for the expression of postjunctional a  2-adrenoceptors thereby rendering all 
responses to a  j-adrenoceptor agonists possessing any a j  efficacy sensitive to 
prazosin. The facilitatory action of All on postjunctional a  2-adrenoceptor- 
mediated responses is apparent only if a  j-adrenoceptors are blocked by prazosin 
or phenoxybenzamine (Dunn et al., 1991a). In this investigation potentiation 
effect of All on UK-14304-mediated responses in the presence of prazosin was 
rauwolscine-resistant, consist out with a  j-adrenoceptor activation. In conclusion 
with regard to potentiation by prior exposure to A ll or L-NAME, it is 
theoretically possible that UK-14304 exerts its actions through combined oq and 
a 2 activation, but the effectiveness of prazosin and the ineffectiveness of 
rauwolscine except in non-selective concentrations makes the simplest 
explanation that it is working entirely via a j .
Inducing tone with PE, U-46619 or 5HT had no effect on responses to UK-14304. 
However KC1 increased responses. The simplest explanation for the potentiation 
of the response to UK-14304 is the of slight depolarisation induced by KC1 affects 
the receptor-response coupling of UK-14304, as suggested by Lues and
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Schumann (1984) in potentiation of BHT-920 in rabbit aorta. The potentiating 
effect of KC1 is consistent with this possibility. In agreement with this possibility 
Hondeghem and colleagues (1986) showed that partial depolarisation by KC1 
potentiated noradrenaline-induced contraction in the rabbit aorta and porcine 
coronary artery. The effect of angiotensin can be explained by assuming that 
angiotensin acts on a common pathway linked to different receptors which is part 
of the excitation-contraction coupling mechanism. These results have parallels 
with previous results showing that a stimulating factor (the presence of a 
stimulating agent e.g. All or inhibition of NO or partial depolarisation by KC1) is 
necessary for expression of the contractile responses to (X2-adrenoceptor agonist.
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CHAPTER 3 
Subtypes of al-Adrenoceptors 
in Rabbit Saphenous Vein
3.1 Introduction
The rabbit lateral saphenous vein has a mixed functional population of a j  and 
o^-adrenoceptors (Purdy et al., 1980; Schumann & Lues, 1983). It represent a 
tissue which has a mixed population of postjunctional a-adrenoceptors where 
ot2-adrenoceptors dominate to a greater extent (Daly et al., 1988a).
In carotid artery where only a \ -adrenoceptors are present, we classified 
ai-adrenoceptor subtypes using selective a  j-adrenoceptor agonists and 
antagonists. We chose saphenous vein to characterise the a\-adrenoceptor 
subtypes which co-exist with ot2-adrenoceptors in this tissue. It is possible that 
different selective a  \ -adrenoceptor agonists and antagonists interact with 
(X2 -adrenoceptors. The aim of this study is to examine and interpret 
pharmacological subclassification of a  \ -adrenoceptors proposed by Muramatsu 
and co-workers (1990) in this atypical preparation that has both postjunctional 
c l i  and ot2-adrenoceptors.
Methods
Vessel isolation and preparation are as described in section 4.2.2.
Results
3.2 Potency of PE
PE produced concentration-dependent contractions in the isolated lateral 
saphenous vein. PE produced isometric contraction with a pD2 value of 5.84 
and a maximum contraction of 3.36 ±0.15g.
Consecutive CCRC's to PE were not reproducible, there being a significant 
increase in the maximum response with time (Figure 3.1)
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3.3 Effects of a-adrenoceptor antagonists
Prazosin produced concentration dependent rightward displacement of PE 
CCRC (Figure 3.2a). The pA2 value for prazosin was 8 and the slope of Schild 
plot was close to unity (0.98), indicating competitive antagonism (Table 3.1).
HV-723 produced parallel shifts of concentration-response curve to PE (Figure 
3.2b). Schild regression analysis yielded line with pA2 value of 7.97 and slope 
of 0.61, different from unity, indicating non-competitive antagonism (Table 
3.1).
5MU produced concentration-dependent shifts in the potency of PE without 
reducing the maximum response (Figure 3.3a). The pA2 value for 5MU was 7.2 
and slope of the Schild plot was 0.81, different from unity, indicating 
non-competitive antagonism (Table 3.1).
Figure 3.3b demonstrates the effect of various concentration of the selective 
a  i-adrenoceptor antagonist WB-4101 on responses to PE. The pA2 value for 
WB-4101 was 8 .6  and slope of the Schild plot was different from unity (0.74), 
indicating non-competitive antagonism (Table 3.1).
The irreversible antagonist chloroethylclonidine (100pM) that preferentially 
alkylates ajg-adrenoceptors, failed to reduce significantly the maximum 
response to PE but produced small shifts in the potency of PE. The tissues were 
treated with CEC (100pM) for 30 minutes followed by washout of the 
irreversible antagonist for an additional 30-45 minutes. The shift in potency of 
PE produced by CEC (IOOjiM) was 12.8 times (Figure 3.4a).
0C2 -ad ren o cep to r an tagonist delequam ine produced  sh ift o f 
concentration-response curve to PE (Figure 3.4b). The pA2 value was 8.3 and 
slope of the Schild plot was different from unity (0.7), indicating non­
competitive antagonism (Table 3.1).
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The rank order of potencies for these a-adrenoceptor antagonists were as 
follows: WB-4101>delequamine>prazosin >HV-723>5MU (Table 3.1).
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Figure 3.1
Effect of time on oc-adrenoceptor agonist PE cumulative dose response curve. 
The first CCRC to agonist is represented by (O) while second CCRC to agonist 
represented by (■). Results are expressed as % of the maximum response of 
the first control CCRC to PE. Statistically significant differences are 
represented by * p<0.05, ** 0.001<p<0.01, paired Student's t-test.
Each point represents mean ± s.e.mean (n=6 ).
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Effects of ai-adrenoceptor antagonists a) prazosin 0.0 lpM  (■ ) or 0.1 pM (A) 
b) HV-723 0.0 lpM  (□), 0.1 pM (A) or lpM  (■) on responses to PE (O) in the 
rabbit isolated lateral saphenous vein. Results are expressed as % of the 
maximum response of the control CCRC in the absence of antagonist.
Each point represents mean ± s.e.meam (n=6).
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Table 3.2.1
an tagon ist P^ 2 slope
prazosin 8 0.98
(7.6-8.95) (0.93-1.1)
5MU 7.2 0.81
(6.77-8.85) (0.74-0.95)
WB-4101 8 .6 0.74
(7.93-9.37) (0.63-0.91)
HV-723 7.97 0.61
(7.75-8.19) (0.502-0.706)
delequamine 8.31 0.71
(7.94-8.69) (0.56-0.83)
List of pA2 values with the slopes of the Schild plots (With 95% confidence 
limits) for a-adrenoceptor antagonists against responses to phenylephrine in the 
rabbit isolated lateral saphenous vein.
pA2 values were determined from a regression analysis of the logarithm of dose 
ratio -1 against the negative logarithm of the molar concentration of the 
antagonist.
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pA2 values obtained for the a-adrenoceptor antagonists using Schild analysis by 
plotting log (DR-1) on the y-axis against the log M [antagonist] on the x-axis 
and fitting using linear regression, a  1-adrenoceptor antagonists a) HV723 b) 
WB4101 c) prazosin and d) 5-MU and a 2 -adrenoceptor antagonist e) 
delequamine aganist contractions to phenylephrine in the rabbit isolated lateral 
saphenous vein.
Each point represents an individual experiment.
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F igure 3.3
Effects of ai-adrenoceptor antagonists a) 5-methylurapidil 0.01 |iM (□), 0.1 pM 
(A) or l|aM (■ ) b) WB-4101 0.01|iM (■) or 0.1|xM (A) on control responses 
to PE (O) in the rabbit isolated lateral saphenous vein. Results are expressed as 
% of the maximum response of the control CCRC in the absence of antagonist.
Each point represents mean ± s.e.meam (n=6).
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F igu re  3.4
Effects of a) treatment with chloroethylclonidine (A); tissues were treated with 
100p,M for 30 minutes followed by washout for an additional 30-45 minutes b) 
selective (^-adrenoceptor antagonist delequamine 0.1 p,M (■ ) or lpM  (A) on 
control response to PE (O) in the rabbit isolated lateral saphenous vein. Results 
are expressed as % of the maximum response of the first control CCRC to PE in 
the absence of CEC or delequamine.
Each point represents mean ± s.e.mean (n=6).
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Discussion
Although phenylephrine is considered to be a selective a  \-adrenoceptor agonist 
(Starke et a l,  1975) and has been used to activate the postjunctional 
a  i-adrenoceptors, the potency of phenylephrine in the rabbit saphenous vein is 
low (with pD2 value of 5.84) and it is possible that phenylephrine mediates 
contraction by activation of a 2 -adrenoceptors. A difficulty is that postjunctional 
oq and a  2 -adrenoceptors do not co-exist in a simple manner and they interact at 
the level of a common post-receptor site in the events leading to contraction. 
Schumann and Lues (1983) reported that phenylephrine responses were 
insensitive to prazosin but sensitive to rauwolscine in the rabbit saphenous vein. 
In another report rauwolscine competitively antagonised the contractile 
responses to phenylephrine in the rabbit saphenous vein with pA2 of 7.16 
(Alabaster et al, 1985).
In the current study prazosin competitively inhibited contractile responses to 
phenylephrine with a pA2 value of 8. The selective a 2 -adrenoceptor antagonist 
delequamine (Brown et al, 1993) inhibited phenylephrine-induced contractions. 
The pA2 and slope were 8.3 and 0.7 respectively. If it is accepted that 
delequamine is highly selective for ct2 -adrenoceptors then this would be 
consistent with phenylephrine contraction being mediated by a p  and 
a 2-adrenoceptors and corollary is that its responses can be attenuated by 
antagonists of either receptor type.
In dog saphenous vein concentration-dependent contractile response curves 
obtained to selective a  2 -adrenoceptor agonist BHT-920 were progressively 
displaced to the right of controls by delequamine. Schild analysis of these data 
gave a pA2 of 10 with slope of 0.85. Pretreatment of the tissues with 
phenoxybenzamine at a concentration (lOnM) which irreversibly inactivates the 
a  i-adrenoceptors did not modify the antagonist effects of delequamine. In
89
rabbit aorta delequamine was a weak antagonist of phenylephrine-induced 
contractions. pA2 was 6.05 with slope of 0.9 (Brown et al., 1993). Also in the 
present study in preconstricted preparations of rat carotid artery induced by NA 
delequamine produced weak relaxation of NA-induced contractions compared 
with rauwolscine. Thus delequamine does appear to be highly selective for ot2 .
3.3.2 Subtype of 0 4 -adrenoceptor mediating contraction is consistent 
with ccjl
In this preparation there is evidence for phenylephrine-induced contraction 
being mediated by 0 4 -  and ot2-adrenoceptors and synergistic effect of a p  and 
ot2-adrenoceptors. The relatively low absolute pA2 values for prazosin, in rabbit 
saphenous vein is consistent with blockade of the type as defined by 
Muramatsu and co-workers (1990). An alternative explanation is that all 
antagonists appear to have low potency due to the synergism between 0 4 -  and 
oc2-adrenoceptors but the 0 4  l  hypothesis will be discussed further.
The 04  L-adrenoceptors are also less sensitive to WB-4101 and 5-MU (pKB: 
approximately 8) and are relatively resistant to CEC. HV-723 (Muramatsu et 
al., 1990) can subdivide the a i L-adrenoceptor into two subtypes: 
(HV723-low, <lnM) and 0 4 ^  (neither 0 4 3  or °4 l)  (HV723-high). In this study 
pA2 of HV-723 was 7.97 that is less than 9. Therefore the subtype of 
0 4 -adrenoceptor mediating contraction in this preparation can be interpreted as 
the 0 4  L type* Lack of inhibition of phenylephrine-induced contraction by CEC 
supports that the response is mediated by a subtype other than 0 4 3  or a j D 
subtypes. The same pattern was seen when 0 4 -adrenoceptor mediated 
contraction of the guinea-pig ileum by phenylephrine was examined. 
Phenylephrine-mediated contraction was not affected by treatment with CEC. 
In addition both WB-4101 and 5-MU antagonised the 0 4 -adrenoceptor mediated 
contraction with low affinity (Abel et al, 1995).
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In the present investigation, prazosin, WB-4101, 5-MU and HV-723 
antagonised the phenylephrine-mediated contraction with lower affinity than we 
expected for a \-adrenoceptors. In the classical a\-adrenoceptor preparation, rat 
aorta, WB-4101 and 5-MU competitively antagonised contractions to NA. The 
pA2 values were 9.21 and 8.12 respectively (Aboud et a l, 1993). HV-723 
competitively inhibited the contractile responses induced by phenylephrine in 
rabbit thoracic aorta and rat aorta. The pA2 values were 8.71 and 9.21 
respectively (Muramatsu et al., 1990). Although they are low for ot2 , the 
affinities of these antagonists are much higher than we would expect for 
ot2-adrenoceptors. This indicates that in this preparation the relative resistance 
of responses to PE shown by the selective a  j-adrenoceptor antagonists may be 
because PE interacts not only with the aj-adrenoceptors. However the data can 
support the presence of the prazosin-low affinity sites ( a \ ^ -adrenoceptors) 
which have also been detected in many other tissues: human, dog and rabbit 
prostates, human coronary vein, rat vas deferens, rat anococcygeus muscle, rat 
portal vein, dog femoral artery and vein (Muramatsu et a l, 1995). The 
a  1L-adrenoceptor is found in vascular smooth muscle (the thoracic aorta) of the 
guinea-pig and is insensitive to inactivation by CEC. In addition to having a 
low affinity for prazosin (>lnM), they also have a relatively low affinity 
(l-10nM) for WB-4101 (Abel et al, 1995).
The present data may fit with the a 1L subtype within the a i Hj and 
subclassification proposed by Muramatsu and co-workers (1990), although this 
subtype has not yet been identified by molecular cloning techniques. In 
conclusion, our study demonstrates that in the rabbit isolated lateral saphenous 
vein: i) subtype of a  j-adrenoceptor mediating contraction is a 1L. ii) contraction 
induced by the selective a\-adrenoceptor agonist phenylephrine is mediated via 
a  i - and a 2-adrenoceptors.
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CHAPTER 4
Investigation of the Rabbit Coronary 
Ligation Model of Heart Failure
Section 1: Introduction
4.1.1 Introduction to heart failure
Chronic heart failure is a clinical syndrome characterised by the inability of the 
heart to provide adequate nutrient supply to metabolically active tissues. Or in 
pathophysiological terms, heart failure can be defined as an inability of the heart 
to deliver blood (oxygen) at a rate commensurate with the requirements of the 
metabolising tissues despite normal or increased ventricular filling pressures 
(Dargie & Mcmurray, 1993).
Sudden cardiac death claims an estimated 350 000 lives per year in the United 
States and between 50 000 and 100 000 lives a year in the United Kingdom. 
There are numerous underlying diagnoses in patients suffering sudden cardiac 
death. In 75% of cases, the underlying pathology causing heart failure in patients 
with sudden cardiac death is coronary heart disease (Pye & Cobbe, 1992). In the 
Framingham study, initiated in 1949, hypertension was the major etiological 
factor in 75% of cases of chronic heart failure (CHF), with coronary heart disease 
(CHD) accounting for only 10% of cases (Mckee et al., 1971). Recent data from 
USA, in particular from the very large SOLVD (Study Of Left Ventricular 
Dysfunction) registry and treatment groups, show that coronary artery disease is 
now the major cause of CHF. Coronary disease accounts for three-quarters of 
CHF in white male patients. Hypertension is a much more common cause of heart 
failure in blacks (36% of cases) and hypertension and dilated cardiomyopathy are 
more common in females (Teerlink et al., 1991).
92
4.1.2 Basic changes and adaptations in heart failure
The enhanced peripheral resistance seen in advanced heart failure results from 
increased sympathetic tone, stimulation of vascular a  j-adrenoceptors by increased 
circulating catecholamines, and increased levels of their circulating humoral 
vasoconstrictors (Zelis et al., 1981). The increased sympathetic tone in heart 
failure is associated with a loss of myocardial surface p-adrenoceptors with a 
selective loss of the myocardial contractile response to p-adrenoceptor stimulation 
(Bristow et a l, 1986).
Plasma noradrenaline levels are elevated in CHF patients and correlate with 
increased mortality. Endogenous catecholamines such as noradrenaline can act as 
potent vasoconstrictors, which mediate vasoconstriction via vascular 
a-adrenoceptors, ensuring blood flow to vital vascular beds (Cohn et al., 1984). 
Elevated levels of circulating noradrenaline may result from exaggerated 
adrenomedullary release of the catecholamine, increased efferent sympathetic 
outflow from the central nervous system, facilitated release of noradrenaline from 
adrenergic nerve terminals, impaired peripheral reuptake of this catecholamine, or 
a combination of these mechanisms. The impairment of pump performance in 
chronic heart failure leads to the activation of various neurohumoral compensatory 
mechanisms, aimed at maintaining peripheral vascular tone and tissue perfusion 
(Davis eta l, 1988; Jenning & Esler, 1990).
A reduction in cardiac output is often accompanied by an increase in ventricular 
filling pressures and by alterations in systemic and pulmonary arterial pressures. 
Abnormalities in vasomotor tone are a well-known component of chronic heart 
failure (Francis, 1987). It has been described as a condition of generalised 
neurohumoral excitation, characterised by activation of the sympathetic nervous 
and renin-angiotensin systems, increases in plasma vasopressin concentration, and 
parasympathetic withdrawal. Although the endogenous release of neurohormones
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can exert deleterious haemodynamic and metabolic effects, these substances also 
play an important beneficial role in the support of systemic blood pressure, 
cardiac contractility and glomerular filtration rate. Furthermore, prolonged 
neurohormonal activation is accompanied by changes in end-organ responsiveness 
that can significantly modify the effects of neurohormonal agonists. Finally 
abnormally high concentrations of circulating hormones, neurotransmitters and 
other toxins may also injure remaining muscle, giving rise to the concept of a 
self-perpetuating vicious cycle of deteriorating cardiac function (Swedberg et al., 
1990).
In heart failure, circulating adrenaline is increased much less than is 
noradrenaline, although if one combines all studies that have measured adrenaline 
in heart failure there is a two to three-fold increase. The magnitude of 
neurohormonal activation appears to adversely affect the prognosis of patients 
with heart failure, at least with respect to circulating levels of plasma 
noradrenaline and renin activity. Although the precise mechanism responsible for 
these relations are unclear, it is known that neurohormonal activation is a 
progressive phenomenon in patients with heart failure. Contemporary concepts 
suggest that heart failure is associated with a maladaptive overcompensation of 
neurohormonal response to impairment of cardiac function and the initiation of a 
vicious cycle of progressive neurohormonal activation, further decline in cardiac 
function, etc. (Bristow, 1993).
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Mechanisms for generalised sympathetic activation and parasympathetic 
withdrawal in heart failure. ACh= acetylcholine; CNS= central nervous system; 
E= epinephrine; Na+= sodium; NE= norepinephrine, (From Floras, J.S., 1993)
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4.1.3 Changes in vascular system
Zelis and co-workers (1968) found that the ability of the resistance vessels of 
patients with congestive heart failure compared to normal patients to respond to a 
wide variety of endogenous vasodilator stimuli (reactive hyperaemia, hand 
exercise and local heating) and exogenous vasodilator stimuli (intra-arterial 
sodium nitrite) was reduced. In CHF the peripheral vascular response is 
characterised by increased peripheral vasomotor tone at rest that has been 
attributed to multiple factors including increased sodium and water content in the 
arterial wall, neurohormonal activation, reconditioning, and intrinsic abnormalities 
in vascular smooth muscle. Systemic vascular resistance thought to increase as a 
compensation mechanism to maintain arterial pressure and organ perfusion (Zelis 
& Flaim, 1982). It is also conceivable that a rise in total systemic vascular 
resistance is a late event in the pathogenesis of heart failure. Since that the 
smooth muscle cells of the vessel wall can generate considerable intrinsic tone, 
independent of neural or hormonal input, it is possible that the onset of the rise in 
vascular resistance is delayed, in part, by opposing changes in intrinsic vascular 
tone (Pawlowski & Morgan, 1992).
4.1.4 Animal models of heart failure
Several animal models of human congestive heart failure have been developed in 
attempts to reproduce these features to study the pathogenic mechanisms involved 
in this disease. The coronary artery occlusion model of heart failure in the rat has 
been extensively studied. The model has been validated by the measurement of 
haemodynamic variables (Drexler et al., 1985).
The rat with aorta-caval fistula appears to be a relevant experimental model in 
comparison with the high cardiac output heart failure models, and has similar
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humoral characteristics but different local haemodynamic characteristics (Flaim et 
al., 1979). Rats with aortocaval (A-V) fistula, an experimental model of CHF, 
display alterations in renal handling of salt and water that closely mimic those of 
patients with cardiac failure (Winaver et al., 1988).
Rapid ventricular pacing in the dog has been shown to fulfil the clinical, 
radiographic and haemodynamic definitions of congestive heart failure 
(Armstrong et al., 1986). In this model of heart failure, plasma noradrenaline 
gradually increases with advancing symptoms, becoming significantly elevated 
after 1 week of pacing and progressively enhanced as heart failure develops (Moe 
etal., 1989).
Pigs share similar cardiac anatomy and coronary vasculture to that of humans, 
which makes them suitable for the study of human disease processes. Chronic 
pacing results in systemic and diastolic dysfunction with reduced collagen support 
for adjoining myocytes (Spinale et al, 1992).
Adriamycin is a widely used anthracycline antibiotic and possesses cardiotoxic 
properties. This toxic side-effect has been utilised in a number of studies to 
induce heart failure in rabbit. The method involves administration of a toxic dose 
of adriamycin over a prolonged time period sufficient to produce heart failure. 
Rabbits treated chronically with adriamycin developed symptoms of heart failure 
such as lower CO, increased heart weight/body weight ratio (Minatoguchi & 
Majewski, 1994).
Cardiomyopathic male hamsters of the BIO TO-2 strain, a unique experimental 
model of CHF characterised by progressive myocytolytic necrosis of cardiac 
muscle are available in study of CHF (Sole, 1986).
The rabbit coronary ligation model is a relatively straightforward model of left 
ventricular dysfunction. In coronary ligation model it has become recognised that
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collateral flow is the most important determinant of the rate and extent of cell 
death within an ischaemic zone. Collateral flow in the rabbit has been shown to 
be essentially very poor, similar to the human and pig (Maxwell et al., 1987). 
Since in 75% of cases, the underlying pathology causing heart failure in patients 
with sudden cardiac death is coronary heart disease (Maurice & Cobbe, 1992), this 
model produces similar circumstance to coronary heart disease.
98
Section 2: Methods and Materials
4.2.1 Preparation of the model
The model was prepared by M. Hicks and co-workers in the Royal Infirmary, 
Glasgow. Myocardial infarction was produced in male New Zealand white rabbits 
(2.6kg-3.0kg) by ligation of the marginal branch of the left descending coronary 
artery. Male New Zealand white rabbits are pre-medicated with intra-muscular 
Hypnorm (0.3mg /kg, fluanisone (lOmg/ml); fentanyl citrate (0.315mg/ml). The 
anterior and left lateral chest wall was shaved and cleaned with Hibidil in 
isopropyl alcohol. The animals were further sedated with intravenous midazolam 
(0.25-0.5mg/kg) via the marginal ear vein to allow edotracheal incubation. 
Anaesthesia was maintained using an inhaled mixture of 1% Halothane, 1% 
nitrous oxide and 1% oxygen. The animal was placed on aprewarmed table and 
body temperature maintained by means of a thermostatically controlled heating 
mat. The left circumflex artery (which supplies a significant part of the left 
ventricle) was identified. This artery was ligated with an Ethicon suture at the 
mid-point between the atrioventricular groove and the cardiac apex. The infarcted 
region rapidly becomes blue and is easily seen. The infarcted region could be 
assessed and if it was not large enough a second suture was placed more proximal 
to the first until a satisfactory infarct was obtained. Sometimes the infarct size 
was so large that cardiac output fell sufficiently to produce a marked reduction in 
peripheral pulse volume. Intractable ventricular fibrillation would follow soon 
after and only by untying the coronary ligature could there be any hope of the 
animal recovering. Such animals rarely survived and are not included in analysis. 
Animals were treated with intravenous quinidine (15mg/kg, marginal ear vein) 5 
minutes prior to ligation of the coronary artery to reduce the incidence of 
arrhythmia.
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The chest wall was closed using three 2/0 interrupted catgut sutures placed 
through the chest wall around the ribs adjacent to the wound and drawn firmly 
together thus splinting the ribs. Antibiotics were administered at the end of the 
procedure by intramuscular injection (ampicilin 25mg/kg and cephalexidine 
15mg/kg). Post-operative analgesia was administered (0.2mg/kg intramuscular 
buprenorphine) at 30 minutes and 6 -8  hours after the procedure, and as considered 
to be required. Intravenous fluids were administered at the end of the procedure 
(15-20ml normal saline).
4.2.2 Duration of coronary ligation in rabbit
The development of chronic heart failure was allowed to proceed over either eight 
or sixteen weeks. Sham operated animals underwent a similar procedure but no 
ligation was performed. Procedures were performed in pairs with one 
sham-operated and one ligation animal placed onto the protocol at weekly 
intervals so that they reached the end of protocol at the same time. In eight weeks 
coronary ligated rabbits two groups were studied with the same protocol. In the 
first group (group 1), for preliminary work, four isolated arteries and veins (aorta, 
vena cava, renal artery and renal vein) of sham operated rabbits with mean 
ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits with mean ejection 
fraction of (49.83 ± 2.7), as determined by echocardiography, were investigated. 
We called this group of ligated rabbits as group 1 of LVD (left ventricular 
desfunction).
In the second group (group 2) four pairs of arteries and veins (thoracic aorta and 
vena cava; left renal artery and left renal vein; lateral saphenous artery and lateral 
saphenous vein and finally central ear artery and marginal ear vein) of the sham 
operated with mean ejection fraction of (70.5 ±2.13) and coronary ligated rabbits 
with mean ejection fraction of (46.5 ± 4.4) were studied. We called this group of
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ligated rabbits as group 2 of LVD. In sixteen weeks coronary ligated rabbits one 
group was studied with the same protocols as in eight weeks coronary ligated 
rabbits. In this group four isolated arteries and veins (aorta, vena cava, renal 
artery and renal vein) of the sham operated with mean ejection fraction of (74.57 ± 
1.62) and coronary ligated rabbits with mean ejection fraction of (39.17 ±2.91) 
were investigated.
Arteries and veins were carefully removed with as little connective tissue as 
possible and placed in cold physiological salt solution (PSS). The arterial and 
venous rings were mounted in 10ml isolated organ baths, bathed in Krebs
o
maintained at 37 C and gassed with 95% O2 plus 5% CO2 .
The rings were then placed under different resting tensions: aorta (2-2.5g), renal 
artery (1.5g), lateral saphenous artery (lg), ear artery (lg), lateral saphenous vein 
(1.5g), vena cava (0.5g), renal vein (0.5g) and ear vein (0.5g) which were 
determined by contraction to NA (lpM ) from some preliminary experiments. 
They were allowed to equilibrate for 1 hour before the experiments. Blood
0
vessels were either used immediately or stored at 4 C in Krebs-Henselite solution 
overnight, since Ito and Chiba (1985) have shown that canine intermediate 
auricular artery do not lose activity due to this storage technique. We used 
preparations immediately for relaxation study, but stored overnight for contraction 
study. Our preliminary experiments showed that preparations used in this study
o
did not lose their activity on responses to NA or KC1 due to storage in 4 C 
overnight.
Protocols: Individual vessels were subjected to one of two protocols as follows.
4.2.3 Protocol I: relaxation  study
It was the aim of the present study to assess whether endothelium-dependent or 
-independent relaxations play an important role at the level of larger vessels in a
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model devised to mimic heart failure. However, few data are available on the 
function of conductance vessels throughout the large artery and vein trees in heart 
failure. It is known that large arteries impose low resistance to blood flow. 
Futhermore, large arteries contribute to cardiac load by the conversion of pulsatile 
flow to continuous tissue perfusion. We wished to study the function of larger 
vessels that serve as conduits to deliver oxygenated blood to the body organs in 
arteries and return blood to the heart in veins. Acetylcholine was chosen as 
endothelium -dependent vasodilator and sodium nitroprusside as an 
endothelium-independent vasodilator. To further investigate ATP and adenosine 
were also chosen as vasodilators to study the function of endothelium in addition 
to acetylcholine.
After initial application of tension tissues were left to equilibrate for a 60 min 
period, during which time the tension was re-adjusted to a set value which was 
maintained constant throughout the rest of the experimental day. Each preparation 
was then contracted with KC1 (Krebs solution, Na free and high KC1, 125 mM) 
and allowed to contract for 5-10 min. Following complete washout with normal 
Krebs, an additional 30 minutes equilibration period was allowed. Then all tissues 
were precontracted with NA (lpM ). This induced submaximal contraction in all 
vessels with the exception of the ear vein (see CRC's to NA, Figure 4.23). When 
the NA-induced contraction reached a plateau, cumulative concentration-response 
curves to ACh, SNP, ATP or adenosine were obtained by increasing the 
concentration of the vasodilators in half-log increments. Between each 
concentration-response curve to vasodilator, vessels were washed repeatedly and 
allowed to re-equilibrate for at least one half hour. All concentrations are 
expressed as the final concentration in the organ bath fluid.
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4.2.4 Protocol II: contraction study
The aim of this study was to test sensitivity and neuronal uptake of NA in this 
model of heart failure. The intracellular uptake of noradrenaline is mediated by at 
least two processes, named uptake \ and uptake2- Uptake^ has been identified as 
neuronal uptake of catecholamines into the sympathetic nerve terminals and is 
believed to be the main process terminating the actions of noradrenaline released 
as a neurotransmitter. We used cocaine (l|xM) to inhibit neuronal reuptake of 
noradrenaline.
Initially all tissues were exposed to cumulative concentration of NA 
(lnM-300p,M). Following complete washout, the preparations were left 45 
minutes to re-equilibrate. Then all preparations were contracted with KC1 (Krebs 
solution, Na free and high KC1, 125mM) and allowed to contract for 5-10 min. 
Following complete washout with normal Krebs, an additional 30 minutes 
equilibration period was allowed. Again, tissues were contracted with KC1 (Krebs 
solution, Na free and high KC1,125mM) and allowed to contract for 5-10 minutes. 
Following complete washout with normal Krebs, an additional 30 minutes 
equilibration period was allowed. Then preparations were exposed cumulatively 
to NA. Following complete washout, the preparations left 45 minutes to 
re-equilibrate. After preincubation with cocaine (lOpM) for 10-15 minutes to 
inhibit neuronal uptake of NA, a final NA CRC was conducted cumulatively.
4.2.5 Histological studies
First experimental arteries and veins were dissected out and cleared of any 
extraneous connective tissue using fine scissors, as much as possible. Glyoxylic 
acid technique (Bjorklund et ah, 1972 and Dr. Ian Montgomery as personal 
communication) was used to demonstrate axons and varicoses of sympathetic
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nerves on these isolated blood vessels. Specimens photographed using a Zeiss 
Axiophot microscope fitted with epifluorescence and a barrier filter block at 
390-420pm. Photomicrographs were taken using Fujichrome Provia 1600 colour 
reversal film.
4.2.6 Calculations and Statistics
The relaxation response to vasodilator (ACh, SNP, ATP or adenosine) was 
expressed as percentage of the contraction generated by NA (l|iM ) against which 
it was tested. Response to each contractile agonist is expressed as absolute 
tension (g). Response to first NA CRC also was expressed as % of first KC1 
(125mM). This would give three useful comparisons: i) it allows some
comparison between the vessels; ii) it lets us see how good NA is at achieving the 
maximum that KC1 can pull; iii) the full contractile potential of each vessel. All 
data are given as mean ± s.e.mean. Significance was always accepted at the 0.05 
level of probability.
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Section 3: Results of experimental heart failure (group 1)
4.3.1 Relaxation to ACh
Acetylcholine induced relaxations in both arteries and veins. Renal artery was the 
least sensitive preparation to acetylcholine (Figure 4.3). At a few individual 
concentrations, in the two veins, there was a significant smaller relaxation in the 
shams. This affected the threshold in the vena cava but not the renal vein. There 
was no pattern of difference between coronary ligated and sham operated rabbits 
after 8 weeks in group 1 (Table 4.1).
4.3.2 Relaxation to SNP
Sodium nitroprusside produced vasorelaxations in all tissues (Figure 4.4). There 
was no difference between coronary ligated and sham operated rabbits after 8 
weeks in group 1 (Table 4.1).
4.3.3 Relaxation to ATP
This agent could induce some relaxations in both arteries and veins (Figure 4.5). 
The veins relaxed more than arteries whose responses were trivial, but in every 
case the response to ATP compared to ACh or SNP was poor in terms of both 
threshold concentration and maximum relaxation attained with in the concentration 
range tested. In relaxation to ATP, there was no difference between coronary 
ligated and sham operated rabbits after 8 weeks in group 1 .
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Left ventricular ejection fraction values from sham and coronary ligated rabbits 8 
or 16 weeks after operation.
8W(1): rabbits after 8 weeks sham operation or coronary ligation in group 1 
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Figure 4.3
Relaxation to ACh in the four isolated arteries and veins of the sham operated 
(O) with mean ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits 
(# )  with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in group 
1. Results are expressed as % of maximum response to NA (lpM ) used for 
inducing tone.
Each point represents mean ± s.e.mean (n=6). Statistically significant differences 
are represented by * p<0.05, ** 0.001<p<0.01, Student's t-test.
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Figure 4.4
Relaxation to SNP in the four isolated arteries and veins of the sham operated (O ) 
with mean ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits ( # )  
with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in group 1. 
Results are expressed as % of maximum response to NA (l|uM) used for inducing 
tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.5
Relaxation to ATP in the four isolated arteries and veins of the sham operated 
(O ) with mean ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits 
(# )  with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in group 
1. Results are expressed as % of maximum response to NA (lfiM) used for 
inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Table 4.1 
Vessel
Aorta 
Vena cava 
Renal artery 
Renal vein
pic50 (Ach) 
sham
6 .8 8  ±0.15 
6.72 ±0.12
7.05 ± 0.07 
6.31 ±0.36
pIC5 0  (Ach) 
Ligated
6.51 ±0.36
7.02 ±0.13 
6.76 ±0.2 
7.26 ±0.16
pIC5 0  (SNP) 
sham
5.97 ±0.1 
5.58 ±0.15 
5.57 ±0.12 
5.74 ±0.37
pIC5o (SNP) 
Ligated
5.98 ±0.17 
6.25 ± 0.06 
5.8 ±0.3 
5.28 ±0.34
Comparison of PIC50 expressed as the -log of the IC50 (concentration producing 
50% of the maximum relaxation attained within the range tested) in sham and 
coronary ligated rabbits in response to ACh and SNP after 8 weeks operation in 
group 1 .
Data are expressed as mean ± s.e.mean (n=6 ).
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Table 4.2
Vessel pIC25 (Ach) pIC25 (Ach) pIC25 (SNP) pIC25 (SNP)
sham Ligated sham Ligated
Aorta 7.03 + 0.3 6 .8  ±0.23 6.52 ±0.11 6.78 ±0.2
Vena cava 6.77 ±0.2 7.09 ±0.35 6.08 ±0.12 6.41 ±0.22
Renal artery 6.93 ±0.18 6.89 ±0.24 5.9 ±0.18 6.4 ±0.46
Renal vein 6.51 ±0.42 7.24 ±0.15 5.9 ±0.43 5.55 ±0.21
Comparison of pIC25 expressed as the -log of the IC25 (concentration producing 
25% of the maximum relaxation to NA (lpM ) used for inducing tone) in sham and 
coronary ligated rabbits in response to ACh and SNP after 8 weeks operation in 
group 1 .
Data are expressed as mean ± s.e.mean (n=6 ).
I l l
4.3.4 Relaxation to adenosine
Adenosine induced small relaxations in both arteries and veins (Figure 4.6). The 
veins relaxed more than arteries, but generally response to adenosine compared to 
ACh or SNP was poor. In relaxation to adenosine, there was no difference 
between coronary ligated and sham operated rabbits after 8 weeks operation in 
group 1 .
4.3.5 Relaxation to p-adrenoceptor agonist isoprenaline
Isoprenaline induced relaxations in both arteries and veins (Figure 4.7). In every 
case response obtained to isoprenaline within the range tested compared to ACh or 
SNP was smaller. Renal artery was the most sensitive one and produced the 
maximum relaxation (20-26%). In relaxation to P -adrenoceptor agonist 
isoproterenol, there is no difference between coronary ligated and sham operated 
rabbits after 8 weeks operation in group 1 .
4.3.6 Contraction to NA
Initially all tissues were exposed to cumulative concentrations of NA 
(1 nM-300(iM). Renal artery and aorta had much greater maximum responses to 
NA compared with the veins (Figure 4.8). In vasoconstriction to NA, there was no 
difference between coronary ligated and sham operated rabbits after 8 weeks 
operation in group 1 .
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Figure 4.6
Relaxation to adenosine in the four isolated arteries and veins of the sham 
operated (O) with mean ejection fraction of (69.67 ± 3.25) and coronary ligated 
rabbits (# )  with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in 
group 1. Results are expressed as % of maximum response to NA (lpM ) used for 
inducing tone.
Each point represents mean ± s.e.mean (n=6 ).
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Figure 4.7
Relaxation to isoprenaline in the four isolated arteries and veins of the sham 
operated (O) with mean ejection fraction of (69.67 ± 3.25) and coronary ligated 
rabbits (# )  with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in 
group 1. Results are expressed as % of maximum response to U-46619 (0.1 pM) 
used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.8
First CCRC to NA in the four isolated arteries and veins of the sham operated (O ) 
with mean ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits ( # )  
with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in group 1. 
Responses are expressed as tension (g).
Each point represents mean ± s.e.mean (n=6).
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Figure 4.9
First CCRC to NA in the four isolated arteries and veins of the sham operated 
(O ) with mean ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits 
( # )  with mean ejection fraction of (49.83 ± 2.7) after 8 weeks operation in group 
1. Results are expressed % of the maximum response to KC1 (125mM) after 
CCRC to N A in each preparation.
Each point represents mean + s.e.mean (n=6).
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4.3.7 Response to KC1
All preparation were contracted with KC1 (Krebs solution, Na free and high KC1, 
125mM) and allowed to contract for 5-10 min. Contraction to KC1 in the first or 
second test showed no significant difference, and arteries had greater maximum 
contractions compared with veins. However, response to KC1 was similar in 
coronary ligated and sham operated rabbits after 8 weeks operation in group 1 
(Figure 4.10).
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Response to KCI in the four isolated arteries and veins of the sham operated with 
mean ejection fraction of (69.67 ± 3.25) and coronary ligated rabbits with mean 
ejection fraction of (49.83 ± 2.7) after 8 weeks operation in group 1. a) response 
to KCI after CCRC to NA b) response to KCI after first KCI.
Each point represents mean ± s.e.mean (n=6).
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Section 4: Results of experimental heart failure (group 2)
In experiments on tissues from this group of rabbits the data was essentially similar 
to group 1 where the same tissues and protocols were employed. The protocols 
were similar selected for an extension of all concentration range for NA since in 
group 1. The greatest concentration used did not produce a convincing maximum 
in the CRC to NA in some of the tissues tested in group 1 (compare Figure 4.8 with 
Figures 4.22 and 4.23). This follows a straightforward description of the data from 
group 2  followed by an our all consideration of groups of 1 and 2 .
4.4.1 Relaxation to ACh
Acetylcholine induced relaxations in all arteries and veins. Ear vein, saphenous 
vein and aorta were most sensitive in terms of threshold and concentration 
producing 50% maximum relaxation of tone. Saphenous vein and aorta produced 
the greatest maximum relaxations (78-90%). In renal artery and ear vein high 
concentration of acetylcholine (>lpM ) produced paradoxical contraction. We 
investigated mechanism of this contraction in renal artery. Indomethacin (1 jiM ), 
which blocks the production of prostaglandins, did not affect the contraction 
evoked by acetylcholine in renal artery. In the presence of L-NAME (lOOpM) 
acetylcholine produced poor relaxation but L-NAME failed to affect contraction 
produced by acetylcholine in high concentrations. Atropine an antagonist of 
muscarinic receptors, blocked the contraction produced by acetylcholine. These 
results suggest that contraction to ACh in this artery is related to muscarinic 
receptors located in smooth muscle cells which are sensitive to high concentration 
of ACh.
Saphenous artery and ear artery had the poorest response to acetylcholine. It is 
possible that one reason for this is that narrow lumens in these preparations make it
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difficult to avoid damage to the endothelium when stainless-steel L-shaped hooks 
are passed through the lumen. However relaxation to the endothelium-independent 
agent SNP was also poor in these preparations (see Figure 4.12 and 4.15).
In ear and renal veins the concentration response curves to ACh were clearly not 
monophasic, in the ear vein a rebound contraction occurred at high concentration 
of ACh and in the renal vein, in contrast there was a further relaxation phase at 
high concentration of ACh. In relaxation to acetylcholine, there was no difference 
between coronary ligated and sham operated rabbits after 8 weeks operation in 
group 2 (Figures 4.12 and 4.13, Table 4.3).
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Figure 4.11
Representative trace recording of cumulative relaxation responses to ACh in the 
rabbit isolated renal artery and effects of an inhibitor of cyclooxygenase 
indomethacin (l|iM ), an inhibitor of NO synthase L-NAME (lOOpM) and an 
antagonist of muscarinic receptors atropine (lpiM). Renal artery was incubated 45 
minutes with indomethacin and atropine but L-NAME was added 10-15 minutes 
prior to the onset of CCRC to acetylcholine.
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Figure 4.12
Relaxation to ACh in the four isolated arteries of the sham operated (O) with 
mean ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with 
mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results 
are expressed as % of maximum response to NA (ljuM) used for inducing tone.
Each point represents mean ± s.e.mean (n=6). Statistically significant differences
are represented by * p<0.05, unpaired Student's t-test.
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Figure 4.13
Relaxation to ACh in the four isolated veins of the sham operated (O ) with mean 
ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with mean 
ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results are 
expressed as % of maximum response to NA (lpM ) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
123
-8 3*-8 -7 3*-7 -6 3*-6 -5 3*-5
renal artery
aorta
ear artery
saphenous artery
saphenous vein
venacav
renal vein    .
'»-aw^ rr« * ,"*m\---J
r**" "'"fimhml fc
lg  (saphenous vein, renal artery and aorta)
0.5g (other preparations)
Figure 4.14
Representative trace recording of cumulative relaxation responses to ACh in the 
rabbit isolated four pairs of arteries and veins: thoracic aorta and vena cava; left 
renal artery and left renal vein; lateral saphenous artery and lateral saphenous vein 
and finally central ear artery and marginal ear vein. All tissues were precontracted 
with NA (lp.M). This induced submaximal contraction in all vessels with the 
exception of the ear vein. When the NA-induced contraction reached a plateau, 
cumulative concentration-response curves to ACh was obtained by increasing the 
concentration of the vasodilator in half-log increments.
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Table 4.3
Vessel
Aorta
Vena cava
Renal artery
Renal vein
Saphenous
artery
Saphenous
vein
Ear artery 
Ear vein
pIC5 0  (Ach) 
sham
7.44 ± 0.06 
6.56 ±0.3 
6.54 ± 0.67
6.75 ± 0.37 
6.53 ± 0.74 
8 .0 2  ± 0.11
6.44 ±0.18
7.71 ±0.23
pic50 (Ach) 
Ligated
7.35 ± 0.09 
6.93 ±0.41
7.09 ± 0.09
7.13 ±0.39
6.13 ±0.42
7.89 ±0.16
6.33 ±0.16
7.89 ±0.1
Maximum 
relaxation % 
sham
76.7 ±6.11
44.23 ± 9.59
43.66 ±6.05
66.21 ±6.72 
7.88 ±1.35
77.02 ± 6 .8  
31.51 ±2.85
87.6 ± 7.54
Maximum 
relaxation % 
Ligated
91.97 ±4.33 
*
59.39 ±6.01
55.02 ±5.31 
69.55 ± 8.92 
20.79 ± 8.82 
90.43 ±5.1 
38.08 ±9.5 
84.15 ±8.36
Comparison of PIC50 that is expressed as the -log of the IC50 (concentration 
producing 50% of the maximum relaxation attained within the range tested) in 
four pairs of arteries and veins of the coronary ligated and sham operated rabbits 
after 8 weeks operation in group 2. Maximum relaxation is expressed as % of NA 
(ljuM) used for inducing tone.
Data are expressed as mean ± s.e.mean (n=6). Statistical comparisons with
controls were carried out using unpaired Student's t-test * p<0.05.
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4.4.2 Relaxation to SNP
Sodium nitroprusside produced vasorelaxations in all tissues. As for acetylcholine, 
ear vein, aorta and saphenous vein were the most sensitive and also produced the 
greatest maximum relaxations within the concentration range tested. Again 
saphenous artery and ear artery had the poorest response to sodium nitroprusside. 
Together with the poor response to ACh this suggests that these tissues are 
relatively insensitive to the effects of NO whether it is done by SNP or released by 
endothelium. In general sensitivity to SNP was one log order less than to ACh in 
the shams. In ear vein and renal vein differences were 0.4 and 1.5 log units 
respectively. There was no difference between coronary ligated and sham operated 
rabbits after 8 weeks operation in group 2  in response to sodium nitroprusside 
(Figures 4.15 and 4.16, Table 4.4).
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Figure 4.15
Relaxation to SNP in the four isolated arteries of the sham operated (O ) with 
mean ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with 
mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results 
are expressed as % of maximum response to NA (lpM ) used for inducing tone.
Each point represents mean + s.e.mean (n=6 ). Statistically significant differences 
are represented by * p<0.05, unpaired Student's t-test.
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Figure 4.16
Relaxation to SNP in the four isolated veins of the sham operated (O) with mean 
ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with mean 
ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results are 
expressed as % of maximum response to NA (HiM) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.17
Representative trace recording of cumulative relaxation responses to SNP in the 
rabbit isolated four pairs of arteries and veins: thoracic aorta and vena cava; left 
renal artery and left renal vein; lateral saphenous artery and lateral saphenous vein 
and finally central ear artery and marginal ear vein. All tissues were 
precontracted with NA (lp,M). This induced submaximal contraction in all 
vessels with the exception of the ear vein. When the NA-induced contraction 
reached a plateau, cumulative concentration-response curves to SNP was obtained 
by increasing the concentration of the vasodilator in half-log increments.
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Table 4.4
Vessel PIC5 0  (SNP) PIC5 0  (SNP) Maximum
relaxation%
sham Ligated sham
Aorta
Vena cava
Renal artery
Renal vein
Saphenous
artery
Saphenous
vein
Ear artery 
Ear vein
6.33 ±0.13 
5.66 ± 0.26 
5.46 ±0.1
5.37 ±0.2
5.36 ±0.17
7.09 ±0.18
5.21 ±0.09
7.23 ± 0.2
6.38 ±0.07
6.07 ± 0.23 
5.82 ±0.16
5.61 ±0.21
5.71 ±0.28 
7.3 ± 0.2
5.72 ±0.16
6.92 ± 0.26
90.29 ±2.14
67.89 ± 5.4
47.97 ± 6.39 
59.96 ± 9.29 
22.87 ±1.16 
98.26 ± 0.77 
46.713 ±5.93 
87.63 ±4.54
Maximum 
relaxation% 
Ligated
95.81 ±1.20
74.39 ± 6.43
63.67 ±8.1 
59.99 ± 8.84 
33.47 ± 6.99
98.39 ±1.73
60.81 ±5.27 
87.25 ± 3.9
Comparison of PIC50 expressed as the -log of the IC50 (concentration
producing 50% of the maximum relaxation attained within the range tested) in 
four pairs of arteries and veins of the coronary ligated and sham operated rabbits 
after 8 weeks operation in group 2. Maximum relaxation expressed as % of NA 
(lpM ) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Table 4.5
Vessel pIC2 5  (Ach) pIC2 5  (Ach) pIC2 5  (SNP) pIC2 5  (SNP)
sham Ligated sham Ligated
Aorta 7.76 ± 0.13 7.7 d= 0.11 6.88±0.12 7.01 ±0.08
Vena cava 6.57 ±0.28 7.18 ±0.35 6.17 ±0.33 6.43 ±0.3
Renal artery 7.2 ±0.08 7.14 ±0.13 5.47 ±0.16 6.07 ±0.12
*
Renal vein 7.24 ±0.41 7.69 ±0.31 5.57 ±0.32 5.91 ±0.29
Saphenous 4.5 ±0.14 5 ± 0.36
artery
Saphenous 8.25 ±0.14 8.15 ±0.16 7.6 ±0.18 7.76 ±0.17
vein
Earartery 5.4±0.25 6.1 ±0.26 5.23±0.22 5.69±0.18
Ear vein 8.03 ±0.18 8.12 ±0.11 7.46 ±0.02 7.36 ±0.21
Comparison of pIC25 expressed as the -log of the IC25 (concentration producing 
25% of the maximum relaxation to NA (lpM ) used for inducing tone) in four 
pairs of arteries and veins of the coronary ligated and sham operated rabbits after 
8 weeks operation in group 2. Relaxation expressed as % of NA (l|iM ) used for 
inducing tone.
Each point represents mean ± s.e.mean (n=6). Statistical comparisons with
controls were carried out using unpaired Student's t-test * p<0.05.
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4.4.3 Relaxation to ATP
This agent induced relaxations in both arteries and veins. The veins relaxed more 
than arteries, but in arteries responses to ATP compared to ACh and SNP were 
smaller. Relaxation CRC's to ATP were of similar form to those for ACh and SNP 
in veins, but on a molar basis sensitivity was less. Saphenous vein was the most 
sensitive and produced the maximum relaxation (45%). Among the veins, as for 
ACh and SNP the two veins tested in group 2, ear and saphenous veins show the 
greatest relaxations. In relaxation to ATP, there was no difference between 
coronary ligated and sham operated rabbits after 8 weeks operation in group 2 
(Figures 4.18 and 4.19).
4.4.4 Relaxation to adenosine
Adenosine induced relaxations in both arteries and veins. The veins relaxed more 
than arteries, but generally responses to adenosine compared to ACh or SNP were 
poor. In relaxation to adenosine, there was no difference between coronary ligated 
and sham operated rabbits after 8 weeks operation in group 2 (Figures 4.20 and 
4.21).
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Figure 4.18
Relaxation to ATP in the four isolated veins of the sham operated (O ) with mean 
ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with mean 
ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results are 
expressed as % of maximum response to NA (lpM ) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.19
Relaxation to ATP in the four isolated arteries of the sham operated (O ) with 
mean ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with 
mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results 
are expressed as % of maximum response to NA (1 pM) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.20
Relaxation to adenosine in the four isolated veins of the sham operated (O ) with 
mean ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits ( # )  with 
mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results 
are expressed as % of maximum response to NA (lpM ) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.21
Relaxation to adenosine in the four isolated arteries of the sham operated (O ) 
with mean ejection fraction of (70.5 ±2.13) and coronary ligated rabbits (# )  with 
mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation group 2. Results 
are expressed as % of maximum response to NA (lpM ) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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4.4.5 Contraction to NA
Initially all tissues were exposed to cumulative concentrations of NA 
(1 nM-300|iM). Aorta, ear artery and ear vein were the most sensitive preparations 
(pD2 values: 9.96, 7.04 and 7.8 respectively). Renal artery and aorta had relatively 
very large maximum responses to NA among the arteries (6.7 and 4.3g 
respectively) and saphenous vein had greatest maximum response among the veins. 
In vasoconstriction to NA, there was no difference between coronary ligated and 
sham operated rabbits after 8 weeks operation in group 2 (Figures 4.22 and 4.23, 
Table 4.6).
4.4.6 Response to KC1
All preparation were contracted with KC1 (Krebs solution, Na free and high KC1, 
125mM) and allowed to contract for 5-10 min. Contraction to KC1 in the first or 
second test showed no significant difference and arteries except saphenous vein 
had greater contractions compared with corresponding veins. Renal artery, 
saphenous vein and aorta had the greatest maximum contraction (7, 5 and 4.2g 
respectively). However, the response to KC1 was similar in coronary ligated and 
sham operated rabbits after 8 weeks operation in group 2 (Figure 4.26, Table 4.9).
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Figure 4.22
First CCRC to NA in the four isolated arteries of the sham operated (O ) with 
mean ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits (■ ) with 
mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. Results 
are expressed as % of maximum response to NA (lpM ) used for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.23
Comparison of first CCRC to NA in the four isolated veins of the sham operated 
(O) with mean ejection fraction of (70.5 ±2.13) and coronary ligated rabbits (■ ) 
with mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. 
Results are expressed as % of maximum response to NA (ljiM) used for inducing 
tone.
Each point represents mean ± s.e.mean (n=6).
139
a )
o
A o r t a b ) Renal artery 
140 t
1 2 0 -
100 -
Log[NA](M) Log[ NA] (M)
c ) Saphenous artery1 120 n
100 -
o* 80 -
o
5? 60 -
40 -
20 -
1 0 - 9  - 8  - 7  - 6  - 5 - 4  - 3
d ) Ear artery
Log [N A]( M)
140 -i
120 -
80 -
60 -
20 -
1 0 - 9  - 8  - 7  - 6  - 5  - 4  - 3
Log [NA]( M)
Figure 4.24
Comparison of first CCRC to NA in the four isolated arteries of the sham 
operated (O) with mean ejection fraction of (70.5 ±2.13) and coronary ligated 
rabbits (■ ) with mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in 
group 2. Results are expressed % of the maximum response to KC1 (125mM) 
after CCRC to NA in each preparation.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.25
Comparison of first CCRC to NA in the four isolated veins of the sham operated 
(O) with mean ejection fraction of (70.5 ±2.13) and coronary ligated rabbits (■ ) 
with mean ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. 
Results are expressed % of the maximum response to KC1 (125mM) after CCRC 
to NA in each preparation.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.26
Response to KCI on the four isolated arteries and veins o f the sham operated with 
mean ejection fraction of (70.5 ± 2.13) and coronary ligated rabbits with mean 
ejection fraction of (46.5 ± 4.4) after 8 weeks operation in group 2. a )  response to 
KCI after CCRC to NA in the four arteries b )  response to KCI after CCRC to NA 
in the four veins c )  response to a second exposure to KCI after first KCI in the 
four arteries d) response to a second exposure to KCI after first KCI in the four 
veins.
Each point represents the mean ± s.e.mean (n=6).
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Table 4.6
Vessel pD2
1 st
CCRC
toNA
sham
pD2
1 st
CCRC 
to NA
Ligated
Pl>2 
2 nd 
CCRC 
to NA
sham
Pl> 2 
2 nd 
CCRC 
to NA
Ligated
Pl>2
3rd
CCRC
to NA
+cocaine
sham
pD2
3rd
CCRC
to NA
+cocaine
Ligated
Aorta 6.96 ± 0.08 6.72 ±0.28 7.09 ± 0.07 6.98 ± 0.25 6.88 ±0.09 6.72 ±0.18
Vena
cava
6.23 ±0.18 5.95 ±0.15 6.33 ±0.23 5.8 ± 0.22 6.28 ±0.11 5.89 ± 0.23
R. artery 6.07 ± 0.08 6.11 ±0.16 6.34 ±0.11 6.57 ± 0.22 6.28 ±0.1 6.48 ±0.2
R. vein 6.46 ±0.21 6.29 ±0.17 6.51 ±0.15 6.09 ±0.1 6.39 ±0.12 6.34 ±0.17
S. artery 6.43 ±0.13 6.72 ±0.18 6.46 ±0.08 6.69 ±0.11 7.09 ± 0.06 7.32 ±0.2
S. vein 6.86 ±0.16 6.33 ±0.17 6.44 ±0.08 6.28 ±0.15 7.24 ± 0.09 7.12 ± 0.17
Ear
artery
7.04 ± 0.03 6.65 ±0.2 6.34 ±0.14 6.09 ±0.13 6.99 ±0.11 7.04 ±0.1
Ear vein 7.8 ±0.25 7.72 ±0.13 7.89 ±0.16 7.77 ±0.14 7.79 ±0.1 7.57 ±0.12
Comparison of NA pD2 expressed as the -log of the E C 50 (concentration 
producing 50% of the maximum response) of NA in four pairs of arteries and 
veins of the coronary ligated and sham operated rabbits after 8 weeks operation in 
group 2. Initially all tissues were exposed to cumulative concentration of NA 
(1 nM-300p,M). Following washout, all preparations were contracted with KCI 
(125mM). Following washout, tissues were contracted again with KCI (125mM). 
Following washout, preparations exposed cumulatively to NA. Following 
washout, the preparations contracted with NA cumulatively in presence of cocaine 
(lpM ) that added 10-15 before to inhibit neuronal uptake of NA.
Each point represents mean ± s.e.mean.(n=6).
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Table 4.7
Effect of cocaine (lfiM) on CCRC to NA in different preparations of the coronary 
ligated and sham operated rabbits that show significant difference.
preparation pD2  of CCRC pD2  of CCRC
to NA to NA + Cocaine
ear artery sham 6.34 ±0.14 6.99 ±0.11 **
ear artery Ligated 6.09 ±0.13 7.04 ±0.1 **
saphenous vein sham 6.44 ±0.08 7.24 ±0.09 ***
saphenous vein Ligated 6.28 ±0.15 7.12 ±0.17***
saphenous artery sham 6.46 ±0.08 7.09 ± 0.06 *
saphenous artery Ligated 6.69 ±0.11 7.32 ± 0.2 *
Comparison of pD2 that is expressed as the -log of the EC5q (concentration 
producing 50% of the maximum response) of NA in the presence and absence of 
cocaine (lpM ) in ear artery and saphenous vein or artery of the coronary ligated 
and sham operated rabbits after 8 weeks operation in group 2 .
Data are expressed as mean ± s.e.mean (n=6 ). Statistical comparisons with 
controls were carried out using paired Student's t-test, * p<0.05, ** 0.01<p<0.001,
*** p<0 .0 0 1 .
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Table 4.8
Vessel Maximum Maximum Maximum Maximum Maximum Maximum
response rresponse response response response response
1st CCRC 1st CCRC 2ndCCRC 2ndCCRC 3rd CCRC 3rd CCRC
to NA to NA to NA to NA to NA to NA
+cocaine +cocaine
Aorta 4.26 ±0.36 5.75 ± 0.73 6.4 ±0.54 6.44 ± 1.01 5.89 ±0.57 7.05 ±0.81
* *
Vena 1.19 ±0.33 1.56 ±0.16 1.5 ±0.3 1.74 ± 0.21 1.58 ±0.24 1.82 ±0.18
cava
R. artery 6.71 ±0.61 6.65 ±0.32 7.61 ±0.62 7.07 ±0.49 6.25 ±0.67 5.73 ±0.32
R. vein 1.48 ±0.19 1.6 ±0.38 1.54 ±0.26 2.08 ±0.73 1.48 ±0.23 1.75 ±0.37
S. artery 2.34 ±0.34 2.91 ±0.19 2.53 ±0.41 3.35 ±0.3 2.34 ±0.44 2.76 ±0.24
S.vein 2.92 ±0.34 3.1 ±0.49 3.32 ±0.43 3.63 ±0.53 3.09 ±0.41 3.53 ±0.5
ear 1.79 ±0.29 1.37 ±0.19 2.2 ±0.34 1.72 ±0.31 2.05 ±0.32 1.5 ±0.33
artery
earvein 0.2±0.04 0.31 ±0.06 0.45±0.07 0.46±0.05 0.28±0.03 0.41 ±0.09
Comparison of maximum response expressed as tension (g) of NA in four pairs of 
arteries and veins of the coronary ligated and sham operated rabbits after 8 weeks 
operation in group 2. Initially all tissues were exposed to cumulative 
concentration of NA (lnM-300|iM). Following washout, then all preparations 
were contracted with KCI (125mM). Following washout, again, tissues were 
contracted with KCI (KCI, 125mM). Following washout, preparations exposed 
cumulatively to NA. Following washout, the preparations contracted with NA 
cumulatively in presence of cocaine (IjjM) that added 10-15 before to inhibit 
neuronal uptake of NA. Maximum response is expressed as tension (g).
Each point represents mean ± s.e.mean (n=6). Statistically significant differences
are represented by * p<0.05, unpaired student's t-test.
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Table 4.9
Vessel Maximum Maximum Maximum Maximum
response (g) response (g) response (g) response (g)
First KCI First KCI Second KCI Second KCI
sham Ligated sham Ligated
Aorta 3.61 ±0.37 4.76 ±0.71 4.9 ±0.4 5.8 ± 0.72
Vena cava 1.07 ±0.26 1.32 ±0.12 1.27 ±0.18 1.18 ±0.31
Renal artery 6.34 ±0.7 5.86 ±0.42 7.09 ±0.59 7.06 ±0.24
Renal vein 1.23 ±0.29 1.25 ±0.15 1.04 ±0.17 1.09 ±0.15
Saphenous 2.31 ± 0.37 2.79 ± 0.19 2.59 ± 0.35 3.15 ± 0.26
artery
Saphenous 5.17 ± 0.3 
vein
Ear artery
5.93 ± 0.45 5.06 ± 0.31 5.48 ± 0.48
1.76 ±0.26 1.29 ±0.37 2.09 ±0.27 1.55 ±0.28
Ear vein 0.32 ± 0.06 0.47 ± 0.03 0.36 ± 0.06 0.5 ± 0.04
Comparison of contractions to KCI (125mM) in four pairs of arteries and veins of 
the coronary ligated and sham operated rabbits after 8 weeks operation in group 2 . 
Initially all tissues were exposed to cumulative concentration of NA 
(lnM-300pM). Following washout, all preparations were contracted with KCI 
(125mM). Following washout, tissues were contracted again with KCI (125mM). 
Contraction to KCI is expressed as tension (g).
Data are expressed as mean ± s.e.mean (n=6).
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4.4.7 Effect of cocaine treatment
Cocaine (1 jiM) was used to inhibit neuronal uptake of NA in the isolated arteries 
and veins. All the tissues tested from sham, only in ear artery and saphenous artery 
or vein was the 3rd CRC to NA i.e. in the presence of cocaine, shifted to the left 
indicating increased sensitivity to NA. In the saphenous vein and ear artery there 
occurred despite a fall in sensitivity between the first and second tests in the 
absence of cocaine. In the ear artery cocaine allowed recovery to a value not 
unexpectedly different from the first test, but in saphenous vein the test in cocaine 
exceeded even in value of the first test (This also occurred in arteries, although no 
change occurred between the first two tests). These effects (and non-effect) of 
cocaine were reduced similarly in both sham and 8 weeks ligated rabbits (Table 
4.7).
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Figure 4.27
CCRC to NA and effect of cocaine (lpM ) in the isolated aorta and vena cava of 
the sham operated rabbits with mean ejection fraction of (70.5 ± 2.13) and 
coronary ligated rabbits with mean ejection fraction of (46.5 ± 4.4) after 8 weeks 
operation in group 2. The CCRC to NA after 2 KCI (125mM) represented by (□ ) 
while (A) represents CCRC to NA in presence of (lpM ) cocaine.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.28
CCRC to NA and effect of cocaine (l|iM ) in the isolated renal artery and renal 
vein of the sham operated rabbits with mean ejection fraction of (70.5 ± 2.13) and 
coronary ligated rabbits with mean ejection fraction of (46.5 ± 4.4) after 8 weeks 
operation in group 2. The CCRC to NA after 2 KCI (125mM) represented by (□ ) 
while (A) represents CCRC to NA in presence of (lpM ) cocaine.
Each point represents mean ± s.e.mean (n=6). Statistically significant differences
are represented by * p<0.05, paired Student's t-test.
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Figure 4.29
CCRC to NA and effect of cocaine (lfxM) in the isolated saphenous artery and 
saphenous vein of the sham operated rabbits with mean ejection fraction of 
(70.5 ±2.13) and coronary ligated rabbits with mean ejection fraction of (46.5 ± 
4.4) after 8 weeks operation in group 2. The CCRC to NA after 2 KCI (125mM) 
represented by (□ ) while (A) represents CCRC to NA in presence of (ljxM) 
cocaine.
Each point represents mean ± s.e.mean (n=6). Statistically significant differences
are represented by * p<0.05, ** 0.001<p<0.01, paired Student’s t-test.
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Figure 4.30
CCRC to NA and effect of cocaine (l|iM ) in the isolated ear artery and ear vein 
of the sham operated rabbits with mean ejection fraction of (70.5 ± 2.13) and 
coronary ligated rabbits with mean ejection fraction of (46.5 ± 4.4) after 8 weeks 
operation in group 2. The CCRC to NA after 2 KC1 (125mM) represented by (□ ) 
while (A) represents CCRC to NA in presence of (1 p,M) cocaine.
Each point represents mean ± s.e.mean. (n=6). Statistically significant differences
are represented by * p<0.05, ** 0.001<p<0.01, paired Student's t-test.
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Staining with glyoxylic acid technique (Figure 1-8)
Sympathetic nerves axons and varicoses demonstrated using the glyoxylic acid 
technique (Bjorklund et al., 1972 and Dr. Ian Montgomery as personal 
communication), were observed on the four pairs of arteries and veins of rabbit as 
a network of bright blue fluorescence.
Figure 1
Aorta: sparse innervation at media/adventitia junction, occassionally in the outer 
media.
Figure 2
Renal artery: less sparse innervation with only a few varicosities at the 
media/adventitia junction.
Eigmg-1
Saphenous artery: dense innervation at adventitia/media junction.
Figure 4
Ear artery: dense innervation at adventitia/media junction and also fine axons 
and varicosities between smooth muscle cells of the outer media.
Figure 5
vena cava: no nerves.
Figure 6
Renal vein: sparse innervation, only 8 -1 0  axons entering the media from the 
adventitia.
Figure-7
Saphenous vein: dense innrevation in media and adventitia.
Figure 8
Ear vein: very little evidence of innervation.
Key to figures
L= lumen A= adventitia M= Media
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Section 5: Results of 16 weeks coronary ligated rabbits
In sixteen weeks coronary ligated rabbits one group was studied with the same 
protocols as in eight weeks coronary ligated rabbits. In this group four isolated 
arteries and veins (aorta, vena cava, renal artery and renal vein) were investigated.
The data from this group is very similar to results obtained in 8 weeks groups. As 
in 8 weeks groups, we were not able to find differences in relaxation responses to 
ACh, SNP, ATP or adenosine and vasoconstriction responses to NA or KC1, 
between coronary ligated and sham operated rabbits after 16 weeks operation. 
Therefore, description of results of this group does not need more details (see 
results of 8 weeks groups).
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Figure 4.31
Relaxation to ACh in the four isolated arteries and veins of the sham operated 
(O ) with mean ejection fraction of (74.57 ± 1.62) and coronary ligated rabbits 
( # )  with mean ejection fraction of (39.17 ± 2.91) after 16 weeks operation. 
Results are expressed as % of maximum response to NA (lpM ) used for inducing 
tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.32
Relaxation to SNP in the four isolated arteries and veins of the sham operated (O ) 
with mean ejection fraction of (74.57 ± 1.62) and coronary ligated rabbits ( # )  
with mean ejection fraction of (39.17 ± 2.91) after 16 weeks operation. Results 
are expressed as % of maximum response to NA (l|uM) that used for inducing 
tone.
Each point represents mean ± s.e.mean (n=6). Statistically significant differences
are represented by * p<0.05, unpaired Student's t-test.
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Table 4.10 
Vessel
Aorta 
Vena cava 
Renal artery 
Renal vein
pic50 (Ach)
sham
7.24 ±0.14 
6.95 ± 0.21 
7.33 ±0.36 
6.51 ±0.13
pIC5o (Ach) 
Ligated
7.32 ±0.05 
6 .6  ±0.19 
7.2 ±0.18 
6.19 ±0.11
pic50 (SNP)
sham
6.41 ±0.12 
5.84 ±0.16 
5.73 ±0.14 
5.64 ±0.15
PIC50 (SNP) 
Ligated
6.33 ± 0.07 
5.57 ±0.17 
5.63 ±0.15 
5.47 ±0.16
Comparison of PIC50 expressed as the -log of the IC50 (concentration producing 
50% of the maximum relaxation attained within the range tested) in sham and 
coronary ligated rabbits in response to ACh and SNP after 16 weeks operation.
Data are expressed as mean ± s.e.mean (n=6 ).
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Table 4.11
Vessel pIC25 (Ach) pIC25 (Ach) pIC25 (SNP) pIC25 (SNP)
sham Ligated sham Ligated
Aorta 7.53 ±0.25 7.56 ±0.08 6.99 ±0.16 6.9 ±0.11
Vena cava 6.93 ±0.39 6.57 ±0.29 6.63 ±0.1 5.88 ±0.3
Renal artery 7.54 ±0.42 7.21 ±0.33 6.05 ±0.2 5.72 ±0.2
Renal vein 6.7 ±0.38 6.78 ±0.3 6.12 ±0.3 5.31 ±0.14 
*
Comparison of pIC25 expressed as the -log of the IC25 (concentration producing 
25% of the maximum relaxation to NA (lpM ) used for inducing tone) in sham 
and coronary ligated rabbits in response to ACh and SNP after 16 weeks 
operation.
Data are expressed as mean ± s.e.mean (n=6 ). Statistical comparisons with 
controls were carried out using unpaired Student's t-test * p<0.05.
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Figure 4.33
Relaxation to ATP in the four isolated arteries and veins of the sham operated 
(O ) with mean ejection fraction of (74.57 ± 1.62) and coronary ligated rabbits 
( # )  with mean ejection fraction of (39.17 ± 2.91) after 16 weeks operation. 
Results are expressed as % of maximum response to NA (l|xM) used for inducing 
tone.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.34
Relaxation to adenosine in the four isolated arteries and veins of the sham 
operated (O) with mean ejection fraction of (74.57 ± 1.62) and coronary ligated 
rabbits ( # )  with mean ejection fraction of (39.17 ± 2.91) after 16 weeks 
operation. Results are expressed as % of maximum response to NA (l|iM ) used 
for inducing tone.
Each point represents mean ± s.e.mean (n=6).
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F igure 4.35
Responses to KCI in the four isolated arteries and veins of the sham operated with 
mean ejection fraction of (74.57 ± 1.62) and coronary ligated rabbits ( # )  with 
mean ejection fraction of (39.17 ±2 .91) after 16 weeks operation, a) response to 
KCI after CCRC to NA b) response to KCI after first KCI.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.36
First CCRC to NA in the four isolated arteries and veins of the sham operated (O ) 
with mean ejection fraction of (74.57 ± 1.62) and coronary ligated rabbits ( # )  
with mean ejection fraction of (39.17 ± 2.91) after 16 weeks operation. 
Responses are expressed as tension (g).
Each point represents mean ± s.e.mean (n=6). Statistically significant differences
are represented by * p<0.05, unpaired Student's t-test.
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Figure 4.37
First CCRC to NA in the four isolated arteries and veins of the sham operated 
(O ) with mean ejection fraction of (74.57 ± 1.62) and coronary ligated rabbits 
(■ ) with mean ejection fraction of (39.17 ± 2.91) after 16 weeks operation. 
Results are expressed % of the maximum response to KCI (125mM) after CCRC 
to NA in each preparation.
Each point represents mean ± s.e.mean (n=6).
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Table 4.12
Vessel P&2
1st CCRC 
toNA
sham
P^2
1st CCRC 
toNA
Ligated
P&2
2nd CCRC 
toNA
sham
P&2
2nd CCRC 
toNA
Ligated
P&2
3rd CCRC 
toNA  
(+cocaine) 
sham
P&2
3rd CCRC 
toNA  
(+cocaine) 
Ligated
Aorta 6.78 ±0.27 6.36 ±0.22 6.85 ±0.19 6.5 ±0.18 6.61 ±0.13 6.43 ±0.12
Vena
cava
5.86 ±0.16 6.18 ±0.14 6.06 ± 0.24 6.23 ± 0.03 5.97 ±0.31 6.15 ±0.14
R. artery 6.15 ±0.11 5.69 ±0.12 6.2 ±0.11 6.05 ±0.12 6.33 ±0.12 6.23 ±0.17
R. vein 6.06 ±0.18 6.23 ± 0.02 6.17 ±0.33 6.16 ±0.06 6.08 ±0.15 6.21 ±0.08
Comparison of NA pD2 expressed as the -log of the EC50 (concentration 
producing 50% of the maximum response) of NA in four arteries and veins of the 
coronary ligated and sham operated rabbits after 16 weeks operation. Initially all 
tissues were exposed to cumulative concentration of NA (lnM-300|±M). 
Following washout, all preparations were contracted with KCI (125mM). 
Following washout, tissues were contracted again with KCI (125mM). Following 
washout, preparations exposed cumulatively to NA. Following washout, the 
preparations contracted with NA cumulatively in presence of cocaine (l|iM ) that 
added 10-15 before to inhibit neuronal uptake of NA.
Each point represents mean ± s.e.mean (n=6 ).
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Table 4.13
V essel Maximum Maximum Maximum Maximum Maximum Maximum
response 
1st CCRC 
to NA
sham
response 
1st CCRC 
to NA
Ligated
response 
2nd 
CCRC 
to NA  
sham
response 
2ndCCRC 
to NA
Ligated
response 
3rd CCRC 
to N A  
+cocaine 
sham
response 
3rd CCRC 
to N A  
+cocaine 
Ligated
Aorta 4.62 ± 0.43 4.05 ± 0.29 5.64 ±0.41 6.78 ±0.35 
♦
5.08 ±0.4 6.54 ±0.34
Vena
cava
1.24 ±0.19 1.56 ±0.22 1.76 ±0.32 1.75 ±0.33 1.66 ±0.18 1.77 ±0.29
R. artery 4.98 ±0.33 5.37 ±0.43 5.28 ±0.46 6.1 ±0.55 4.61 ±0.44 4.83 ±0.41
R. vein 1.4 ±0.38 1.78 ±0.31 1.72 ±0.41 2.15 ±0.37 1.44 ±0.29 2.02 ±0.49
Comparison of maximum response expressed as tension (g) of NA in four arteries 
and veins of the coronary ligated and sham operated rabbits after 16 weeks 
operation. Initially all tissues were exposed to cumulative concentration of NA 
(lnM-300|iM). Following washout, all preparations were contracted with KCI 
(125mM). Following washout, tissues were contracted again with KCI (125mM). 
Following washout, preparations exposed cumulatively to NA. Following 
washout, the preparations contracted with NA cumulatively in presence of cocaine 
(l|iM ) that added 10-15 before to inhibit neuronal uptake of NA.
Each point represents mean ± s.e.mean (n=6). Statistically significant differences 
are represented by * p<0.05, unpaired student's t-test.
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Figure 4.38
CCRC to NA and effect of cocaine (lpM ) in the isolated aorta and vena cava of 
the sham operated rabbits with mean ejection fraction of (74.57 ± 1.62) and 
coronary ligated rabbits with mean ejection fraction of (39.17 ± 2.91) after 16 
weeks operation. The CCRC to NA after 2 KCI (125mM) represented by (□ ) 
while (A) represents CCRC to NA in presence of (1 pM) cocaine.
Each point represents mean ± s.e.mean (n=6).
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Figure 4.39
CCRC to NA and effect of cocaine (l|aM) in the isolated renal artery and renal 
vein of the sham operated rabbits with mean ejection fraction of (74.57 ± 1.62) 
and coronary ligated rabbits with mean ejection fraction of (39.17 ± 2.91) after 16 
weeks operation. The CCRC to NA after 2 KCI (125mM) represented by (□ ) 
while (A) represents CCRC to NA in presence of (1 p,M) cocaine.
Each point represents mean ± s.e.mean (n=6).
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Section 6: Discussion
The results of our present investigation led to 3 major conclusions with respect to 
the model. First the relaxation responses to acetylcholine, sodium nitroprusside, 
ATP and adenosine were not impaired. Second vasoconstrictions to noradrenaline 
were unaltered. Third contractions to KCI (125mM) were preserved in large 
vessels (arteries and veins) in coronary ligated rabbits after 8 or 16 weeks 
compared with a normal control population. This investigation is the first to 
examine endothelium function, smooth muscle responsiveness and a -  
adrenoceptor function in large vessels in this model of heart failure.
4.6.1 Endothelial function
It is known that the endothelium is important in the control of tone in both large 
and small vessels (Griffith et al., 1988). Our finding in relaxations to 
acetylcholine are comparable to those observed in other models of heart failure in 
large vessels in isolated rings of dorsal pedal artery from dogs with 
pacing-induced heart failure (Forster et al., 1989b) and in the coronary and 
peripheral vessels in the same model of heart failure (Forster et al., 1990; Main et 
al., 1991). Recently O'Murchu and colleagues (1994) reported a preserved 
vasorelaxation response to acetylcholine in isolated vascular rings from the 
coronary, renal, and femoral arteries from dogs with heart failure induced by rapid 
ventricular pacing. In another model very similar to our model, in thoracic aorta 
acetylcholine-induced relaxation was identical in control and rats with coronary 
ligation after 1 week (Teerlink et al., 1993).
In contrast to reports indicating normal endothelial function, there are many 
reports that show endothelial dysfunction in resistance arteries in different animal 
models of heart failure (Kaiser et al., 1989; Lindsay et al., 1992; Drexler & Lu,
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1992) and patients with CHF (Kubo et al, 1991; Drexler et al, 1992; Nakamura et 
al, 1994; Hirooka, e ta l,  1994).
Since much of the experimental work in different models of heart failure and 
human has concentrated on the smaller arteries and arterioles, the question arises 
to the functional significance and applicability of the changes in microvascular 
function that are observed in subjects with heart failure. It is possible that 
differences in the size of the vessels obtained from normal or heart failure subjects 
may influence response. In human studies caution should be in the influence of 
treatment or residual minor effects after treatment withdrawal on endothelium 
function or various receptor population in patients with heart failure. Since 
abnormalities of endothelium dependent vasodilation have been shown in several 
cardiovascular diseases, such as hypertension (Tesfamariam & Halpem, 1988)) or 
atherosclerosis (Harrison, et a l, 1987), other conditions associated with 
endothelial dysfunction such as hypertension and atherosclerosis should be 
considered in patients with CHF.
One possible explanation for reduced NO production is that in heart failure states 
cardiac output is reduced and the stimulus for NO production by the peripheral 
circulation would be reduced and this depression represents one local mechanism 
for abnormal control of the vasculature in CHF. But CHF is associated with 
activation of the sympathetic nervous and renin-angiotensin systems. Sustained 
increase of local and circulating noradrenaline concentrations therefore apparently 
is associated with an increase in endothelial NO release, which could reflect a 
com pensatory m echanism  to counterbalance excessive peripheral 
catecholamine-dependent vasoconstriction. In agreement with this possibility 
Noll and co-workers (1994) found that in aorta of cardiomyopathic hamsters 
relaxation response to acetylcholine was enhanced. Increased basal production of 
NO in heart failure consistent with reports in patients with CHF (Drexler et a l, 
1992).
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Reports of endothelium function in heart failure yield conflicting results. One 
reason could be attributed to differences between use of different beds of vascular 
system. As reported by Noll and colleagues (1994) in cardiomyopathic hamsters 
endothelium-dependent relaxation to acetylcholine was altered in aorta, whereas 
in mesenteric resistance arteries the response was not affected.
It is possible that these discrepancies can be attributed to differences among 
different models of heart failure. In cardiomyopathic hamsters, indirect signs of 
haemodynamic changes such as lung weight were assessed and exact 
quantification of the stage of heart failure is not known. In chronic rapid 
ventricular pacing, haemodynamic responses, endocrine changes, and the clinical 
and pathological picture of heart failure are all consistent with naturally occurring 
heart failure. Left arterial pressure was abnormally increased and dogs developed 
clinical evidence of heart failure, including ascites, muscular wasting, regurgitant 
murmurs, pulmonary congestive, tachypnea, and biventricular hypertrophy 
(Armstrong et al., 1986; Kaiser et al., 1989). The heart to body weight ratio was, 
however significantly increased in rats with chronic heart failure induced by 
coronary ligation, as were plasma noradrenaline concentrations (Lindsay et al., 
1992). In the rabbit coronary ligated model we have found no significant 
neuroendocrine changes at 8 weeks but have found a small but significant 
elevation of ANP levels at 16 weeks. Thus pathophysiology of heart failure differ 
with the model used and caution should be used in comparing the different models 
in response to acetylcholine and other agents.
Another possibility may be time that heart failure develop through as suggested 
by Teerlink and colleagues (1993). They found endothelial dysfunction develops 
through time in rats with heart failure induced by coronary ligation. 
Acetylcholine-induced relaxation was normal at 1 week, but severe dysfunction 
was evident at 4 weeks. We allowed the model to develop over either eight or 
sixteen weeks. It is unlikely that the duration of heart failure is responsible for the
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observed acetylcholine response in our study since sham-operated and coronary 
ligated rabbits also produced similar responses after 16 weeks.
Since acetylcholine is the classic endothelium-dependent vasodilator, it was 
chosen as the reference endothelium-dependent vasodilator in our study and other 
models of heart failure. Defective release/production of NO from endothelium, 
reduced responsiveness of vascular smooth muscle to NO, impaired diffusion to 
the underlying smooth muscle, changes in receptor mediated responses, and 
facilitated breakdown of NO may be factors in the attenuation of endothelium- 
dependent relaxation to acetylcholine. Since in many reports in spite of impaired 
relaxation to acetylcholine, relaxation to sodium nitroprusside preserved, it is 
unlikely that the reduced response of vascular smooth muscles to NO and 
facilitated destruction of NO might be involved in the depressed response seen 
with acetylcholine.
The caution here is that the receptors on endothelium mediating the release of 
nitric oxide vary greatly between beds, species and within one branch order of the 
same bed (Angus & Michael, 1992). A test of acetylcholine-mediated release of 
nitric oxide may be affected by a change in the endothelial or by a change in the 
responsiveness of the smooth muscle cells to NO that is not necessarily associated 
with a change in nitric oxide release. Acetylcholine is destroyed by cholinesterase 
and nitric oxide can be inactivated by free radicals. Thus change in activity of this 
enzyme (cholinesterase) or free radicals can affect relaxation to acetylcholine. In 
rat pulmonary artery and thoracic aorta, vasodilation evoked with the calcium 
inophoreA23187 did not differ between rats with heart failure and normal rats 
although ACh-induced vasodilation was impaired in rats with heart failure 
(Ontkean et al., 1991). Since A23187 causes nitric oxide release that is not 
mediated by receptors, it was concluded that receptor-mediated NO release was 
impaired.
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Impaired relaxation response to acetylcholine may be related to a specific defect 
in muscarinic-mediated vasodilation rather than endothelium dysfunction as 
reported by Hirooka and co-workers (1992). In their investigation, the 
vasodilation responses to administration of graded concentrations of acetylcholine 
in the brachial artery, as determined with strain-gauge venous occlusion 
plethysmography, were decreased in the forearm circulation of patients with CHF 
when compared with those of normal control subjects. In contrast vasodilation 
responses to endothelium-dependent vasodilator substance P was similar in 
patients with CHF and in normal subjects. The finding of this study suggest that 
the decreased response to acetylcholine is a specific defect in muscarinic-mediated 
vasodilation (muscarinic receptors and/or postreceptor mechanisms coupled with 
muscarinic) rather than a generalised defect in endothelial production of nitric 
oxide or a change in the responsiveness of smooth muscle cells to NO.
To further investigate this we chose ATP and adenosine as vasodilators to study 
the function of endothelium in this model of heart failure independent of 
muscarinic receptors. Adenosine is a vasodilator in almost all vascular beds, and 
endogenous adenosine regulates blood flow in many organ systems. Both 
endothelium-dependent and endothelium-independent responses to ATP and 
adenosine have been reported (De Mey & Vanhoutte, 1981; Headrick & Berne 
1990; Koga et al., 1992; Fredholm et al., 1994). As in relaxations to 
acetylcholine, relaxations to ATP and adenosine were identical in sham operated 
and coronary ligated rabbits.
According to De Mey and Vanhoutte (1982); Seidel and LaRochelle (1987); 
Luscher and co-workers (1988), arteries generally relax more in response to 
acetylcholine compared to veins. They suggested that the endothelium has a 
much lower modulatory role in veins as compared with the arteries. Their study is 
not consistent with the current findings in some pairs of veins and arteries 
(saphenous vein and ear vein compared with corresponding arteries). Also, the
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ability of veins to relax was confirmed by the observation of their responses to the 
endothelium-independent vasodilator sodium nitroprusside, which like 
acetylcholine evokes relaxation by increasing intracellular concentrations of cyclic 
GMP in smooth muscle cells (Moncada et al., 1991). The poor and low levels of 
relaxation to ATP and adenosine in arteries compared with the veins may be 
related to the low population of purinoceptors or difference in vascular reactivity 
between arteries and veins.
Our data suggest normal stimulated nitric oxide release in systemic larger vessels 
(arteries and veins) in coronary ligated rabbits after 8 or 16 weeks. We failed to 
assess the basal NO activity by measuring the increase in force that can occur 
when arterial and venous segments were exposed to L-NAME. The basal release 
of nitric oxide may be negligible in conduit rabbit vessels, or alternatively, its 
effect on vasomotor tone in large vessels is overridden by other factors. It is 
possible that basal NO release is also unaltered or changed.
4.6.2 Response to sodium nitroprusside
Nitrovasodilators were used as endothelium-independent vasodilators to 
investigate function of smooth muscle cells since like nitric oxide, it directly 
activates smooth muscle guanylate cyclase (Moncada et al., 1991).
Our findings agree with (Kaiser et al, 1989 and Main et al, 1991) in large vessels 
in dogs with pacing-induced heart failure, in aorta of rat with coronary liagation 
(Lindsay et al., 1992) and human with CHF (Kubo et al., 1991; Creager et al., 
1991; Hirooka, et a l, 1994) endothelium-independent relaxations to sodium 
nitroprusside were unaltered. In an in vivo study, recently it was reported that 
vasodilator sodium nitroprusside reduced mean arterial blood pressure to a similar
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extent in vehicle-and adriamycin-treated rabbits that were either anaesthetised or 
pithed (Minatoguchi & Majewski, 1994).
Our current investigation is confirmed by the lack of any difference between 
ligated and sham-operated rabbits in the relaxation response to sodium 
nitroprusside. Thus, a generalised abnormality in function of smooth muscle cells 
is not supported.
4.6.3 Response to KCI
Abnormal function of the contractile apparatus of vessels, can be assessed by 
contraction to potassium chloride. In our study, high potassium chloride 
(125mM) was used as contractile agent. It causes direct smooth muscle 
depolarisation leading to smooth muscle contraction via calcium entry through 
voltage sensitive calcium channels.
We observed that contraction to KCI was not different from control at either 8 or 
16 weeks. Our results agree with other reports (Forster et a l, 1989b; Forster & 
Armstrong, 1990; Forster et a l, 1990) in dogs with pacing induced heart failure 
indicate contraction to potassium chloride (125mM) was unchanged. We suggest 
that there is no general change in contractile apparatus or smooth muscle 
responsiveness in this model of heart failure.
4.6.4 a-adrenoceptor activity
This study demonstrates that the physiological mixed ccj^-agonist noradrenaline 
produced concentration-dependent contractions in arteries and veins from controls 
and rabbits with coronary ligation. Our study agree with some of the reports, in 
pacing-induced CHF in canine coronary arteries (Main et al., 1991), in canine
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femoral artery (Kaiser et al., 1989) and in human with CHF (Kubo et a l,  1989; 
Indolfi et al, 1994) showing vasoconstrictions to noradrenaline were unaltered in 
this model of heart failure.
It has been known that plasma noradrenaline levels are elevated in CHF patients 
and increased circulating catecholamines in chronic heart failure might be 
expected to lead to adrenergic down regulation. However in sharp contrast to 
Pi-adrenoceptors down regulation in failing hearts, the a  i-adrenoceptor 
population is maintained at normal levels in the failing human heart (Bristow et 
a l, 1988). In peripheral vessels some investigators found increased tissue 
sensitivity to adrenergic agents during CHF (Forster et al., 1989a; Forster & 
Armstrong, 1990). Contrary to Forster and co-workers, Main and colleagues 
(1991) found that in pacing-induced CHF in canine coronary arteries, the maximal 
contractile response to methoxamine was attenuated. The data suggest 
a  i-adrenoceptor-mediated constriction is diminished.
Our results indicate that the vascular responsiveness to noradrenaline was 
preserved in this model of heart failure.
4.6.5 P-adrenoceptor activity
Since circulating catecholamines exert a tonic vasodilatory effect on peripheral 
vessels via P-adrenoceptors, we investigated the role of p-adrenoceptors in 
coronary ligated rabbits. It is now well established that P-adrenoceptor function is 
abnormal in the myocardium of patients with CHF. In failing ventricles, there are 
decreased numbers of P-adrenoceptors, reduced isoprenaline-stimulated adenylate 
cyclase activity, and depressed inotropic and chronotropic responsiveness to 
P-adrenoceptor agonists (Bristow et a l , 1986). Bristow and colleagues (1993), 
examined isolated cardiac tissue using radioligand-binding techniques and
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reported that p j-adrenoceptor down regulation occurred in the failing left 
ventricle, whereas there was no change in p2 -adrenoceptors. The fact that 
noradrenaline has greater pj-than p 2-adrenoceptor effects may explain the 
selective down-regulation of P \ -adrenoceptors. In spite of the known 
down-regulation of p j -adrenoceptors in the failing left ventricle, few data in 
peripheral vessels are available.
Since the trigger for P-adrenoceptor desensitisation is thought to be chronically 
elevated circulating catecholamines (Bristow, 1993), this condition should also 
induce desensitisation of peripheral P-adrenoceptors as well as those in the heart.
In the present study we found no change in isoprenaline-induced relaxations in 
coronary ligated rabbits compared with a normal control population. O ur results 
are consistent with prior studies (Frey et a l, 1988; Creager et al., 1991) 
investigating this problem which find no peripheral p-adrenoceptor 
desensitisation.
4.6.6 Effect of neuronal uptake blockade
Arterial plasma noradrenaline is 163% higher in patients with heart failure than in 
control patients. High plasma noradrenaline correlates directly with the 
haemodynamic severity of the disease and inversely with survival (Jenning & 
Esler, 1990). Elevated levels of circulating noradrenaline in CHF may result from 
impaired peripheral reuptake of this catecholamine.
Our results in the present experiment showed that neuronal uptake of 
noradrenaline plays no significant role in aorta, renal artery , renal vein, vena cava 
and ear vein of the rabbit. As reported by Nilsson (1984) neuronal uptake of 
noradrenaline plays a minor role in rat aorta. In spite of clear evidence for a 
substantial effect of cocaine on noradrenaline uptake in a variety of tissues
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(Furchgott et al, 1963), cocaine treatment (l|iM ) had only a very modest effect 
on development of mechanical responses to exogenous noradrenaline in ear 
artery, saphenous vein or artery.
Cocaine has generally been used as the prototype drug for inhibition of neuronal 
uptake of catecholamines. Furchgott and co-workers (1963) showed that a 
maximum potentiation of the response to noradrenaline in rabbit aorta and guinea 
pig and cat left atria could be obtained with 10-30 |liM  cocaine. Since 
catecholamine neuronal uptake is the major means of terminating sympathetic 
neural transmission, the adrenergic response is potentiated by cocaine. Inhibition 
of neuronal uptake by cocaine can have minor effects on responses to exogenous 
noradrenaline in blood vessels, particularly when those blood vessels have a 
network of sympathetic neuroeffector complexes that is small in relation to the 
muscular layer (Billman, 1990). Since cocaine has both a sympathomimetic effect 
(inhibition of neuronal uptake of noradrenaline) and, at higher concentration, a 
local anaesthetic property (Na+ channel blockade), caution should exercised in 
relation to the concentration of cocaine. We used l|iM  cocaine to inhibit neuronal 
reuptake of noradrenaline and avoid the local anaesthetic effect.
These results suggest that the density of sympathetic innervation of mentioned 
preparations are significantly less than that of ear artery and saphenous vein or 
artery. It appears that among arteries and veins that were studied, ear artery and 
saphenous artery or vein have innervation which can influence sensitivity to NA. 
To further investigate this we studied the network of sympathetic nerves stained by 
glyoxylic acid. In agreement with the functional results, it was shown that ear 
artery and saphenous artery or vein have dense innervation but in other preparations 
sparse innervation or in vena cava no nerves were observed.
In the present experiment, effects of cocaine on noradrenaline responses were 
identical in sham operated compared with coronary ligated rabbits. This finding
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may indicate no impairment of noradrenaline neuronal reuptake in this model of 
heart failure.
4.6.7 Conclusion
Models of heart failure usually have a complex pathophysiology so that results are 
difficult to interpret. Furthermore, reports of changes in endothelium function, 
smooth muscle responsiveness, activity of receptors etc. are conflicting. These 
discrepancies could be attributed to differences between in vitro versus in vivo 
experiments, the use of conscious versus anaesthetised animals, the use of 
different beds of vascular system and, potentially, to species differences. Results 
obtained in any model of heart failure have to be interpreted and extrapolated to 
humans with caution. One difficulty in studying the development of heart failure 
has been the lack of a well-characterised animal model that clearly mimics heart 
failure in human. Difficulties in using man in the study of heart failure are the 
usual confounding influence of concomitant pharmacologic therapy and the 
uncertainty associated with identifying the time at which heart failure begins.
Animal models of heart failure have been ones of major surgical trauma, 
myocardial ischemia, and pharmacologic or toxic depression of cardiac function. 
However, all of these models may directly affect neurohormonal factors 
independent of the primary influence of heart failure. A combination of neural, 
humoral, and local factors appears to be involved in the alteration of vascular 
responses seen in heart failure. In the current investigation we have evaluated the 
effects of coronary ligation on rabbits as a model for heart failure. However, the 
syndrome of heart failure eventually involves multiple physiological and 
pathophysiological pathways and different stages. The degree of heart failure as 
well as the aetiology may also play a role in response to agents we used.
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Although the exact degree of heart failure in this model is difficult to determine, it 
clinically corresponds to left ventricular dysfunction.
The results of the haemodynamic measurements suggest that short-term (8  week) 
and long-term (16 week) coronary ligation in the rabbits each corresponds to a 
model of experimental asymptomatic left ventricular dysfunction or minimally 
symptomatic LVD rather than of clinical heart failure. This model of heart failure 
used in this study differs from chronic heart failure models and offers several 
advantages over other models. Technically, it is relatively easy to produce and the 
most important advantage is that we can study very early stage of heart failure. 
Clinical heart failure, as currently recognised by doctors, is an end-stage condition 
that treatment has a limited effect. Since heart failure develops from left 
ventricular dysfunction, study of this stage of heart failure can help to prevent left 
ventricular dysfunction progressing to heart failure. Thus we can investigate 
factors leading to progression of left ventricular dysfunction to heart failure. 
Furthermore, this model produces a similar situation to coronary heart disease, 
which is a very common cause of death in patients with heart failure (Maurice & 
Cobbe, 1992).
There is evidence that the resistance vasculature is altered to some degree in this 
model at both 8 and 16 weeks ligation (unpublished observations). There was 
abnormal function of endothelium-derived vasodilation post-ligation: 
subcutaneous arteries had reduced function, pulmonary arteries had increased 
function. Noradrenaline contraction in rabbit subcutaneous arteries was 
influenced by ligation: threshold was lowered.
In this regard, the results of our study suggest that vasoconstriction to 
noradrenaline and normal stimulation of endothelial NO are preserved in larger 
peripheral conduit vessels. This study provides evidence that large vessel 
physiology is unaltered in this particular model of experimental left ventricular
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dysfunction. This difference between the resistance vessels and large vessels may 
be important since it suggest that experimental heart failure affects that part of the 
circulation which is involved with the control of the peripheral vascular 
resistance. The changes demonstrated here provide a useful model for studying 
the progression of Left ventricular dysfunction to full blown heart failure. These 
findings have highlighted which aspects of vascular function are most abnormal 
and which should be targeted for the therapeutic intervention. Correction of these 
abnormalities can be a useful way in preventing of heart failure.
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